**MitoIntegra: A Unified Translational Framework Bridging Mitochondrial Biology, Traditional Chinese Medicine, and Evolutionary Oncology for Personalized Cancer Care** **Author:** Pasquale Valente, MD, PhD Perplexity AI supported. **Affiliation:** Independent Researcher, Rome, Italy **Date:** March 2026 ### Keywords Mitochondria, Traditional Chinese Medicine, cancer as complex adaptive system, multi-omics, BaGuaNet framework, evolutionary therapy, metabolic reprogramming, mitochondrial quality control, phytotherapy, integrative oncology, personalized medicine, adaptive therapy ## MitoIntegra at a Glance **The Clinical Problem:** Cancer generates systemic mitochondrial dysfunction measurable in biofluids, yet no clinical tool integrates mitochondrial biomarkers with traditional pattern recognition for personalized intervention. **The Solution:** MitoIntegra maps multi-omic data onto eight archetypal mitochondrial phenotypes (BaGuaNet-8), generating interpretable hexagram states that guide personalized TCM-phytotherapy protocols. **The Workflow:** Patient → Multi-omic profiling + TCM syndrome assessment → BaGuaNet-8 scoring → Dominant trigram identification → Hexagram state (64 composite phenotypes) → Personalized intervention protocol → Longitudinal trajectory monitoring → Adaptive adjustment **5 Key Messages:** 1. Mitochondria are the mechanistic bridge between TCM syndromes and molecular oncology 2. BaGuaNet transforms opaque omics into clinically narrated hexagram states 3. TCM phytotherapy demonstrates mechanism-based mitochondrial targeting validated in human and preclinical studies 4. Adaptive therapy guided by mitochondrial biomarkers exploits evolutionary fitness costs of resistance 5. A 4-phase validation roadmap operationalizes the framework ## Abstract Cancer is increasingly understood not merely as an abnormal proliferation of cells, but as a complex adaptive system (CAS) characterized by non-linear evolutionary dynamics, phenotypic plasticity, and multi-layered interactions with the tumor microenvironment (TME) and the host organism. Within this systems perspective, mitochondria emerge as central integrative hubs linking bioenergetics, redox signaling, calcium homeostasis, apoptotic control, retrograde signaling, dynamics, and inflammatory responses. They represent the fulcrum through which cancer orchestrates its survival, evolution, and dissemination. Contemporary research has consolidated this view, demonstrating how mitochondrial reprogramming underlies metabolic plasticity, metastatic competence, therapeutic resistance, immune evasion, and systemic manifestations such as cancer cachexia. MitoIntegra synthesizes these insights into a translational framework that: 1. Treats cancer as an evolutionary-ecological information-processing system shaped by its microenvironment; 2. Positions mitochondria as multi-dimensional network hubs, whose dysfunction propagates from molecular mechanisms to systemic manifestations, including cachexia; 3. Integrates Traditional Chinese Medicine (TCM) syndrome differentiation as a millennia-old system of mitochondrial phenotyping validated by modern molecular biology. The BaGuaNet-Omics computational framework—an interpretable deep learning architecture—maps multi-omic data (genomics, transcriptomics, proteomics, metabolomics, microbiomics, and wearables) onto eight archetypal mitochondrial patterns aligned with classical Bagua trigrams. This semiotic coordinate system transforms opaque high-dimensional data into clinically actionable hexagram states (64 composite phenotypes), enabling dynamic trajectory prediction and preemptive interventions. This is a proposed architecture pending prospective validation. The framework bridges ancient diagnostic wisdom with precision medicine through validated TCM syndrome-biomarker-intervention matching: - Qi deficiency correlates with impaired biogenesis (↓ATP, ↓PGC-1α); - Yang deficiency with OXPHOS dysfunction (↓carnitine, ↓T3/T4); - Yin deficiency with oxidative stress (↑ROS, ↓GSH/GSSG); - Blood stasis with endothelial dysfunction (↑circulating mtDNA, ↓NO). Evidence-based phytotherapeutic interventions (Astragalus membranaceus, Panax ginseng, Cistanche deserticola, Salvia miltiorrhiza, berberine-containing herbs, and curcumin) demonstrate mechanism-based mitochondrial targeting with clinical efficacy in cancer-related fatigue, cachexia prevention, chemotherapy toxicity reduction, and immune evasion. Clinical implementation involves: 1. Multi-level diagnostic integration combining TCM pattern recognition with mitochondrial biomarker panels; 2. BaGuaNet-guided personalized intervention protocols targeting dominant trigram imbalances; 3. Longitudinal trajectory monitoring through hexagram state space; 4. Adaptive therapeutic adjustment based on predicted transitions. This paradigm shift—from black-box prediction to narrative-rich interpretation, from tumor genetics to host-tumor coevolution, and from maximum tolerated dose to ecologically-informed adaptive therapy—offers complementary strategies to enhance treatment efficacy, minimize toxicity, prevent recurrence, and meaningfully improve quality of life. We propose validation roadmaps including retrospective cohort analysis, prospective observational studies, and randomized controlled trials within the Society for Integrative Oncology (SIO) network, alongside explainability studies comparing BaGuaNet interpretability with conventional feature attribution methods. MitoIntegra represents a synthesis of millennia-old empirical wisdom and cutting-edge systems biology, providing a mechanistically grounded, clinically implementable, and evolutionarily informed framework for precision integrative oncology. ## Introduction ### 1.1 Cancer as Complex Adaptive System: The Evolutionary and Process-Oriented Paradigm The traditional somatic mutation theory is evolving toward a process-oriented understanding of cancer as an information-processing system shaped by its microenvironment. This shift emphasizes cellular plasticity and adaptive behaviors, providing a framework to explain phenomena such as tumor reversion and clonal heterogeneity that are not fully captured by a purely gene-centric paradigm. In this view, the tumor is embedded in, and continuously co-constructed by, its ecological context [1][2][3]. Conceiving cancer as a CAS reflects its intrinsically evolutionary nature, characterized by: - Spatial and temporal heterogeneity: Tumor cell populations are composed of clones bearing distinctive genomic, epigenetic, and metabolic profiles. - Non-linear evolutionary dynamics: Darwinian selection operates on heterogeneous clonal populations within fitness landscapes. - Phenotypic plasticity: Rapid metabolic switching (glycolysis ↔ OXPHOS), epithelial-mesenchymal transition (EMT), and stemness modulation enable rapid adaptation to therapeutic pressures. - Multi-level interactions: Tumor-microenvironment coupling (e.g., reverse Warburg effect) and tumor-host coevolution (e.g., cachexia, immune evasion, dysbiosis). - Emergent properties: Collective behaviors (e.g., cooperation via public goods production, spatial self-organization) arise from dynamic interactions among cancer cells, stromal elements, immune cells, and the extracellular matrix. This systems perspective fundamentally transforms therapeutic strategy. Traditional maximum tolerated dose (MTD) chemotherapy inadvertently accelerates resistance evolution by eliminating drug-sensitive populations that would otherwise competitively suppress resistant clones [4][5]. Recent advances in evolutionary game theory models demonstrate that adaptive-optimized therapeutic strategies can prolong tumor control compared to standard dose-dense protocols—while reducing toxicity and preserving high proportions of healthy cells—and extend overall survival compared to conventional MTD approaches [6][7][8]. This evolutionary framework requires real-time biomarker-guided treatment modulation rather than fixed protocols. ### 1.2 Allostasis and Allostatic Load in Oncology The allostasis framework defines health not as static homeostasis, but as the capacity to achieve stability through change in response to chronic stress, including cancer itself. Allostatic load represents the cumulative physiological burden imposed by persistent metabolic and inflammatory dysregulation that creates a permissive terrain for tumor initiation and progression. In chronic TME conditions, persistent activation of NF-kB and TNF-α pathways, coupled with intense T-lymphocyte infiltration, serves as a biomarker of allostatic load contributing to tumor initiation, progression, and metastasis. These chronic inflammatory circuits intersect with mitochondrial dysfunction, promoting ROS overproduction, mtDNA damage, and inflammasome activation, which in turn amplify systemic allostatic burden. Thus, measuring and modulating allostatic load—through metabolic, inflammatory, and mitochondrial biomarkers—becomes an integral component of precision oncology, directly aligned with the MitoIntegra focus on multi-level mitochondrial assessment and intervention. ### 1.3 Mitochondria: The Central Integrative Hub Within this complex systems framework, **mitochondria emerge as the master integrator** connecting all eight hallmarks of cancer through seven functional dimensions[9][10][11]: | Hub Dimension | Mechanisms | Cancer Hallmarks | |---|---|---| | Metabolic Switching | OXPHOS↔glycolysis balance, biosynthetic precursors | Proliferation, invasion, metastasis | | Redox Signaling | mtROS as second messengers, oxidative stress regulation | Apoptosis resistance, immortalization | | Calcium Homeostasis | ER-mitochondria coupling at MAMs, Ca²⁺ buffering | Apoptotic threshold modulation | | Apoptotic Control | Cytochrome c sequestration, Bcl-2 family regulation | Evading cell death | | Retrograde Signaling | Mitochondria-to-nucleus communication, epigenetic modification | Stemness, EMT, genome instability | | Morphological Dynamics | Fission/fusion, spatial repositioning | Motility, invasion, metastasis | | Inflammatory Regulation | NLRP3 inflammasome, mtDNA release, cGAS-STING pathway | Immune evasion, tumor-promoting inflammation | Table 1: Mitochondrial hub dimensions and cancer hallmark connections Recent 2025 research confirms mitochondrial dysfunction as a hallmark of cancer progression, with alterations in mtDNA, energy metabolism, and dynamics significantly contributing to tumorigenesis and therapeutic resistance[12]. Critically, mitochondrial dysfunction extends beyond the tumor—generating systemic effects measurable in biofluids (circulating cell-free mtDNA) and correlating with cancer-related fatigue, cachexia, accelerated aging, and immunosuppression[13]. A groundbreaking January 2025 *Nature* study revealed that cancer cells transfer mtDNA-mutated mitochondria to tumor-infiltrating lymphocytes (TILs) via tunneling nanotubes and extracellular vesicles, impairing T cell metabolism and function, leading to senescence and explaining resistance to immune checkpoint inhibitors[14][15]. This mitochondrial hijacking represents a previously undescribed immune evasion mechanism with profound therapeutic implications. ### 1.4 The Semiotic Gap: From Black-Box Omics to Interpretable Medicine While multi-omic technologies (genomics, transcriptomics, proteomics, metabolomics, microbiomics) and continuous physiological monitoring generate unprecedented data volumes, **clinical interpretability remains a critical bottleneck**[16][17]. Deep learning models achieve strong predictive performance but operate as opaque "black boxes" that clinicians cannot translate into therapeutic narratives, limiting adoption and undermining trust in precision medicine[18]. Traditional Chinese Medicine (TCM) offers **symbolic frameworks**—Yin-Yang, Five Phases (Wu Xing), Eight Trigrams (Bagua)—for describing systemic patterns of change in complex living systems[19][20]. These frameworks, refined over millennia through empirical observation, provide interpretable coordinate systems for multi-omic latent spaces, translating molecular complexity into clinically meaningful pattern configurations. ### 1.5 TCM as Mitochondrial Phenotyping: Molecular Validation of Ancient Wisdom Recent network pharmacology and systems biology research demonstrates profound correspondences between TCM syndrome differentiation (辨证, *bian zheng*) and mitochondrial functional states[21][22][23]: ### Qi Deficiency (气虚): **Clinical:** Fatigue, dyspnea on exertion, spontaneous sweating, weak pulse **Mitochondrial correlate:** Impaired biogenesis, ↓ATP production, ↓PGC-1α **Biomarkers:** ↓ATP/ADP ratio, ↑lactate, ↓cardiolipin, ↓NAD⁺/NADH **Formula:** Sijunzi Tang (四君子汤) — *Panax ginseng, Atractylodes, Poria, Glycyrrhiza* ### Yang Deficiency (阳虚): **Clinical:** Cold intolerance, cold limbs, low back soreness, deep slow pulse **Mitochondrial correlate:** OXPHOS dysfunction, ↓thermogenesis, ↓β-oxidation **Biomarkers:** ↓Carnitine, ↓T3/T4, ↓Complex I activity, ↑acyl-carnitines **Formula:** Jin Gui Shen Qi Wan (金匮肾气丸) — mild to moderate; You Gui Wan (右归丸) — severe deficiency with sarcopenia ### Yin Deficiency (阴虚): **Clinical:** Night sweats, five-palm heat, dry mouth, red tongue, rapid pulse **Mitochondrial correlate:** Oxidative stress, ↑ROS, antioxidant depletion **Biomarkers:** ↑MDA, ↑8-OHdG, ↓GSH/GSSG, ↑mtROS, ↑inflammatory cytokines **Formula:** Liuwei Dihuang Wan (六味地黄丸) — *Rehmannia, Cornus, Dioscorea* ### Blood Stasis (血瘀): **Clinical:** Fixed stabbing pain, dark purple tongue, choppy pulse **Mitochondrial correlate:** Endothelial dysfunction, ↓NO, microvascular stasis **Biomarkers:** ↑Circulating mtDNA, ↑D-dimer, ↓NO bioavailability, ↑homocysteine **Formula:** Taohong Siwu Tang (桃红四物汤) — *Prunus persica, Carthamus, Angelica, Ligusticum* Meta-analyses demonstrate that Qi-tonifying herbs specifically enhance mitochondrial function: *Astragalus membranaceus* increases ATP production by 35-50%, improves Complex I and IV activities, reduces ROS via SOD/catalase upregulation, and activates the AMPK→PGC-1α biogenesis pathway[24][25]. Clinical trials show *Astragalus* reduces chemotherapy toxicity, improves immune function, and decreases cancer-related fatigue by ~30% versus placebo[26]. A 2025 bibliometric analysis confirms growing research interest in TCM's role in cancer immunotherapy through immune system regulation, with major mechanisms including: (1) modulation of immune cell functions (NK cells, T cells, macrophages); (2) inhibition of tumor immune evasion (Treg suppression, PD-L1 downregulation); (3) regulation of immune-related signaling pathways (NF-κB, MAPK, STAT3)[27]. ### 1.6 Objectives and Innovation **MitoIntegra** addresses these converging insights by: **Unifying evolutionary-ecological cancer biology with mitochondrial systems biology:** Integrating Darwinian selection dynamics, game-theoretic cooperation, fitness landscapes, and adaptive therapy principles with mitochondrial hub functions **Validating TCM syndrome-mitochondrial phenotype mapping:** Establishing translational bridge between traditional pattern diagnosis and molecular biomarker profiling **Developing BaGuaNet-Omics computational framework:** Creating interpretable multi-omic integration through eight archetypal mitochondrial dimensions aligned with Bagua structure **Synthesizing evidence-based mitochondria-targeted phytotherapy:** Reviewing mechanistic and clinical data for TCM botanical interventions **Proposing actionable clinical algorithms:** Designing personalized syndrome-biomarker-intervention in matching protocols for integrative oncology **Outlining validation strategies:** Establishing roadmaps for clinical utility assessment within the Society for Integrative Oncology (SIO) network This framework represents a paradigm shift from reductionist single-target approaches to **systems-level mitochondrial modulation**, from static treatment protocols to **evolutionarily-informed adaptive therapy**, and from opaque algorithmic predictions to **narrative-rich interpretable medicine** grounded in both molecular precision and holistic context. ## Part I: Cancer as Evolutionary-Ecological System ### 2.1 Darwinian Selection and Fitness Landscapes Cancer evolution operates through **clonal selection** within heterogeneous tumor ecosystems, where subpopulations compete for limited resources (oxygen, nutrients, space) across spatial niches exhibiting varying selective pressures (hypoxia, acidosis, immune surveillance)[28][29]. **Adaptive fitness landscapes** describe how genetic/epigenetic variants influence cellular fitness (proliferation, survival, invasion capacity) within specific microenvironmental contexts[30]. Robert Gatenby and colleagues at Moffitt Cancer Center demonstrated experimentally that tumors must be investigated and treated as adaptive systems where first principles are Darwinian[2]. Critical insights: **Intratumoral heterogeneity:** Single tumors harbor multiple clonal populations with distinct fitness profiles—high-fitness clones show greater vulnerability to targeted extinction, while moderate-fitness clones maintain genetic diversity and resilience[31] **Context-dependent fitness:** A mutation conferring resistance in drug-exposed environments often imposes fitness costs in drug-free conditions, creating frequency-dependent dynamics exploitable therapeutically[6][32] **Evolutionary predictability:** Parallel evolution and convergent adaptation patterns enable trajectory forecasting and preemptive intervention[33] Mitochondrial function critically influences fitness: cells with intact OXPHOS capacity demonstrate superior metastatic potential, anoikis resistance, and colonization efficiency compared to glycolysis-dependent variants[34][35]. ### 2.2 Game Theory and Intra-Tumoral Cooperation Applying **evolutionary game theory** reveals that cancer cells do not compete purely selfishly—they engage in **cooperation** through production of "public goods"[36][37][38]: **Diffusible growth factors:** VEGF, PDGF promoting collective proliferation **Matrix-degrading enzymes:** Matrix metalloproteinases (MMPs) facilitating collective invasion **Angiogenic signals:** Recruiting vascular supply benefiting the entire tumor **Immunosuppressive factors:** Creating protective niches (TGF-β, IL-10, PD-L1) Public goods production is metabolically costly—creating a "cooperator's dilemma" where "free-rider" cells should theoretically invade. Yet cooperation persists through[37][38]: **Positive assortment:** Genetically similar cells interact preferentially **Spatial structure:** Cooperators form clusters with localized benefits **Nonlinear benefit functions:** Threshold effects where cooperation becomes collectively beneficial **Therapeutic vulnerability:** Disrupting cooperation (e.g., MMP inhibitors, anti-VEGF therapy) can collapse tumor ecosystems when strategically timed[39]. Mitochondrial metabolism coordinates public goods production—OXPHOS provides sustained ATP for growth factor secretion and extracellular matrix remodeling[40]. ### 2.3 The Fitness Cost of Resistance and Adaptive Therapy A foundational evolutionary principle: **mutations conferring drug resistance often reduce fitness in drug-free environments**[6][32][41]. A 2025 experimental study quantified these dynamics in gefitinib-resistant lung cancer cells[32]: In co-cultures with predominantly resistant cells: resistant population grows 33% slower than ancestral sensitive cells. In co-cultures with predominantly sensitive cells: resistant cells grow at similar rates. Gefitinib addition completely reverses competitive dynamics. **Adaptive therapy** exploits this cost by maintaining drug-sensitive populations that competitively suppress resistant clones through dynamic dosing modulation rather than continuous maximum dose[4][5][6]. A January 2025 *PLOS ONE* study using optimal control theory demonstrated that adaptive therapy guided by real-time monitoring of sensitive/resistant cell ratios[8]: Maintains high survival proportions of healthy cells (>60% vs <20% for MTD) Prevents explosive growth of resistant populations. Extends progression-free survival by 2-3× compared to continuous treatment reduces cumulative drug exposure and toxicity. Accounts for patient-specific drug tolerance and tumor burden capacity The strategy cycles between ON periods (when tumor burden exceeds threshold) and OFF periods (when sensitive cells regain competitive advantage), with dosing optimized using Pontryagin's minimum principle to balance tumor suppression, toxicity constraints, and competitive dynamics[8]. **Mitochondrial biomarkers** can guide adaptive therapy decisions: Lactate/pyruvate ratio: Glycolytic (resistant) vs OXPHOS (sensitive) dominance ATP/ADP ratio: Energetic fitness status Circulating mtDNA: Mitochondrial damage reflecting treatment response NAD⁺/NADH: Redox status correlating with drug sensitivity ### 2.4 Tumor-Host Coevolution: The Cachexia Paradigm Cancer operates in continuous bidirectional dialogue with the host organism, representing true **coevolution** with reciprocal adaptations[42][43]. #### Cancer Cachexia Cancer cachexia —responsible for 20-40% of cancer deaths[44][45]—represents a paradigmatic example of how tumor and organism coevolve in a vicious cycle of mutual damage. **Tumor Secretion** The tumor releases factors that alter host homeostasis: · Inflammatory cytokines: TNF-α, IL-6, IL-1β · Catabolic peptides: Proteolysis-inducing factor (PIF), zinc-α2-glycoprotein (ZAG) · Metabolic modulators: Substances that disrupt systemic metabolism 2. **Host Response** The body reacts with widespread systemic damage: · Skeletal muscle: Mitochondrial dysfunction · Adipose tissue: Accelerated lipolysis · Intestinal barrier: Altered permeability · Microbiota: Dysbiosis (imbalance of bacterial flora) · Immune system: Chronic systemic inflammation **Feedback Amplification** Host-derived factors—inflammatory mediators and metabolites produced by dysbiosis—feed back to the tumor, this creates an immunosuppressive microenvironment that paradoxically promotes tumor progression. The result is a self-perpetuating cycle: the tumor damages the body, and the body's impaired response, rather than eliminating the tumor, enhances its growth. ### 2.5 Network Biology and Emergent Properties Cancer as CAS manifests **emergent properties**—collective behaviors not predictable from individual cellular characteristics[49][50]: **Metabolic symbiosis:** Reverse Warburg effect where cancer-associated fibroblasts (CAFs) undergo glycolysis, producing lactate/pyruvate fueling tumor OXPHOS—a two-compartment ecosystem with interdependent metabolism[51][52] **Collective invasion:** Coordinated cell migration guided by leader cells with enhanced mitochondrial biogenesis and OXPHOS capacity[53] **Tumor self-organization:** Spatial patterning emerging from local cell-cell interactions, creating reproducible architectures (tumor cords, necrotic cores, vascular niches) Systems biology employs **network models** describing phenotypes (motility, proliferation, apoptosis) as attractors of dynamical systems within gene regulatory networks, protein-protein interaction networks, and metabolic networks[49]. Mitochondria serve as network hubs whose dysfunction alters entire network topology. ### Therapeutic implications: **Multi-node targeting:** Single-node inhibition often fails—simultaneous disruption of multiple network components required **Exploiting evolutionary dynamics:** Use competition, cooperation disruption, fitness cost of resistance **Microenvironment normalization:** Target CAF metabolism, vascular normalization, immune restoration **Predictive modeling:** Patient-specific computational models forecasting response-resistance dynamics ## Part II: Mitochondria as Multi-Dimensional Network Hub ### 3.1 Seven Functional Dimensions Connecting Cancer Hallmarks Mitochondria operate as **central integration platforms** connecting all eight cancer hallmarks through coordinated regulation across seven functional dimensions[9][10][11]: #### 3.1.1 Metabolic Switching: Glycolysis ↔ OXPHOS Plasticity Contrary to static Warburg effect dogma, cancer cells exhibit **dynamic metabolic flexibility**, oscillating between glycolysis and OXPHOS based on microenvironmental constraints[54][55]: **Hypoxia/nutrient scarcity:** Shift to glycolysis (HIF-1α stabilization, PDK1/3 activation inhibiting pyruvate dehydrogenase) **Normoxia/metastasis:** Upregulate OXPHOS (PGC-1α-mediated biogenesis) providing ATP for cytoskeletal remodeling and invasion **Therapeutic pressure:** Metabolic switching enables escape from glycolysis-targeted therapies OXPHOS-dependent metabolic reprogramming significantly promotes metastasis—rotenone (Complex I inhibitor) reverses EMT phenotype in breast cancer, demonstrating critical role of mitochondrial respiration in metastatic competence[56]. **Reverse Warburg Effect:** CAFs undergo aerobic glycolysis, secreting lactate/pyruvate/ketones imported by tumor cells to fuel OXPHOS and anabolism—a metabolic coupling creating therapeutic vulnerability when disrupted (MCT4 inhibitors blocking lactate export)[51][52]. #### 3.1.2 Redox Signaling: mtROS as Second Messengers Mitochondrial ROS (mtROS) exhibit **dose-dependent biphasic effects**[57]: **Low-moderate levels:** Act as mitogenic second messengers activating MAPK/ERK, PI3K/AKT, stabilizing HIF-1α **High levels:** Trigger mPTP opening, cytochrome c release, apoptosis Cancer cells maintain mtROS in the "proliferative window" through enhanced antioxidant systems (glutathione, thioredoxin, SOD2)[57]. During metastasis, circulating tumor cells face oxidative stress—those maintaining mitochondrial integrity and ROS buffering capacity survive anoikis and colonize distant sites[58]. #### 3.1.3 Calcium Homeostasis and MAMs Mitochondria-associated ER membranes (MAMs) represent **critical integration platforms** for Ca²⁺ signaling, lipid synthesis, and apoptotic regulation[59][60]: **Normal cells:** ER-to-mitochondria Ca²⁺ transfer via IP₃R-VDAC coupling can trigger apoptosis when excessive **Cancer cells:** Remodel MAMs to limit Ca²⁺ transfer (↓IP₃R-VDAC coupling), raising apoptotic threshold **Therapeutic resistance:** Enhanced ER-mitochondria Ca²⁺ coupling in melanoma cells exposed to BRAF inhibitors prevents ER stress-mediated death[61] **PML-P2X7R-NLRP3 complex** at MAMs regulates inflammasome activation—PML downregulation in tumors unleashes exaggerated NLRP3-mediated IL-1β/IL-18 production, creating pro-tumorigenic inflammatory microenvironment[62]. #### 3.1.4 Apoptotic Control: Sequestration of Death Factors Mitochondria guard the **intrinsic apoptotic pathway** by sequestering cytochrome c, Smac/DIABLO, AIF, and endonuclease G[63]. Cancer cells manipulate mitochondrial apoptotic regulation through: **Bcl-2 family rebalancing:** ↑Anti-apoptotic (Bcl-2, Bcl-xL, Mcl-1), ↓Pro-apoptotic (Bax, Bak, Bid) **mPTP resistance:** Altered membrane lipid composition (↑cardiolipin oxidation resistance) **Mitophagy activation:** Selective clearance of damaged mitochondria before they trigger death signals #### 3.1.5 Retrograde Signaling: Mitochondria-to-Nucleus Communication **Mitochondrial retrograde signaling (MRS)** represents mechanisms whereby mitochondrial dysfunction transmits signals to nucleus, altering gene expression[64][65]: **Ca²⁺-calcineurin pathway:** Activates NFAT, NF-κB transcription factors **ROS-mediated signaling:** Oxidative modification of transcription factors **Metabolite signaling:** TCA cycle intermediates (α-ketoglutarate, succinate, fumarate) act as epigenetic modifiers influencing histone demethylases (KDMs) and DNA methylation **NAD⁺/NADH ratio:** Regulates SIRT1 deacetylase activity, influencing PGC-1α and p53 MRS implicated in EMT induction and breast cancer stem cell generation[65]. Oncometabolites (2-hydroxyglutarate from IDH mutations, succinate from SDH loss, fumarate from FH loss) globally alter epigenetic landscape, promoting tumorigenesis. #### 3.1.6 Morphological Dynamics: Fission, Fusion, Repositioning Mitochondrial morphology dynamically regulates cancer phenotypes[66][67][68]: | Process | Key Proteins | Function | Cancer Role | |---|---|---|---| | Fusion | MFN1/2, OPA1 | Network formation, MMP maintenance, OXPHOS optimization | ↓MFN2 promotes EMT and metastasis; hyperfusion confers chemo-resistance | | Fission | DRP1, FIS1 | Fragmentation for mitophagy, spatial redistribution | ↑DRP1 increases motility and invasion; accumulation at leading edge | | Mitophagy | PINK1-Parkin, BNIP3, FUNDC1 | Quality control, damaged mitochondria clearance | Removes pro-apoptotic mitochondria, maintains fitness | | Biogenesis | PGC-1α, NRF1/2, TFAM | Generates new mitochondria | Essential for metastatic colonization and CSC maintenance | Table 2: Mitochondrial dynamics in cancer progression **Metastatic repositioning:** During invasion, mitochondria accumulate at cell leading edges, providing localized ATP for actin polymerization, focal adhesion turnover (FAK phosphorylation), and membrane protrusion[69]. **Mitochondrial transfer:** Cancer cells acquire mitochondria from mesenchymal stem cells (MSCs), T cells, and CAFs via tunneling nanotubes (TNTs) and extracellular vesicles, restoring OXPHOS capacity and conferring therapy resistance[70][71]. Groundbreaking 2025 research revealed cancer cells transfer mtDNA-mutated mitochondria to TILs, impairing T cell metabolism and causing immunosuppression—a novel immune evasion mechanism[14][15]. #### 3.1.7 Inflammatory Regulation: NLRP3 Inflammasome and mtDAMPs Mitochondria orchestrate inflammatory responses through multiple mechanisms[72]: **NLRP3 inflammasome activation:** mtROS and cytoplasmic mtDNA (leaked through mPTP or released via mitophagy) trigger NLRP3→caspase-1→IL-1β/IL-18 maturation **cGAS-STING pathway:** Cytoplasmic mtDNA (double-stranded) activates cGAS→STING→IRF3→type I interferon response **Mitochondrial DAMPs (mtDAMPs):** Circulating mtDNA fragments, cardiolipin, N-formyl peptides, ATP act as systemic inflammatory signals In cancer: dysregulated inflammasome activity creates immunosuppressive, pro-angiogenic microenvironments; circulating mtDAMPs correlate with cachexia severity and systemic inflammation[73]. Phytochemicals like baicalein (*Scutellaria baicalensis*) suppress cGAS-STING activation by restoring mitochondrial function, preventing mtDNA release in KRAS/p53-driven lung tumorigenesis[74]. ### 3.2 Mitochondrial Quality Control: The Triad of Biogenesis, Dynamics, and Mitophagy **Mitochondrial quality control (MQC)** integrates three processes maintaining functional mitochondrial networks[75][76]: **Biogenesis:** PGC-1α→NRF1/2→TFAM cascade generates new mitochondria **Dynamics:** Fusion (MFN1/2, OPA1) creates interconnected networks allowing content mixing and complementation; fission (DRP1) segregates damaged units **Mitophagy:** PINK1-Parkin pathway, receptor-mediated pathways (NIX/BNIP3, FUNDC1) selectively eliminate dysfunctional mitochondria Mitochondrial quality control—integrating proteostasis, mitophagy, dynamics, and biogenesis—exerts opposite, context‑dependent effects in neurodegeneration versus cancer. In post‑mitotic neurons, dysfunction of MQC leads to lethal oxidative stress and progressive cell loss, whereas in cancer it promotes selection of adaptive clones with enhanced survival and plasticity. This dichotomy manifests in epidemiology: patients with Parkinson’s disease have reduced cancer risk, while oncologic patients show lower incidence of Alzheimer’s disease. In neurodegeneration, restoring MQC is protective, whereas in cancer, selective inhibition of MQC components can unmask vulnerabilities. MitoIntegra leverages this polarity by supporting MQC in non‑malignant tissues (to mitigate **treatment** toxicity and aging) while exploring mitocans that collapse MQC selectively in OXPHOS‑dependent tumors. **3.2.1 mtUPR and Mitochondrial Proteostasis** The mitochondrial unfolded protein response (mtUPR) coordinates nuclear and mitochondrial transcription to maintain proteostasis under stress. In tumors, chronic activation of mtUPR supports survival under hypoxia and nutrient scarcity, contributing to resistance to chemo‑ and radiotherapy. Pharmacologic activation of the mitochondrial protease ClpP (e.g., ONC201/TR-57) induces proteostatic collapse in mitochondria, triggering selective apoptosis in OXPHOS‑dependent cancer cells while sparing normal tissues. Within MitoIntegra, mtUPR activity is conceptualized as a **BaGuaNet latent axis** influencing trigram patterns associated with stress adaptation versus exhaustion, guiding the choice of interventions that either bolster mtUPR in vulnerable tissues or inhibit it in tumors. ### 3.3 Mitochondria in Metastasis and Dormancy #### 3.3.1 Metastatic Cascade: Bioenergetic Requirements During metastasis, mitochondria undergo **strategic repositioning** toward the leading edge of migrating cancer cells, generating local ATP hotspots that fuel membrane protrusion, cytoskeletal remodeling, and focal adhesion turnover. Metastasis requires sequential mitochondrial adaptations[34][78][79]: **Local invasion:** ↑Fission, leading-edge accumulation, ATP for matrix degradation **Intravasation:** ROS buffering, anoikis resistance requiring intact OXPHOS **Circulation survival:** Metabolic dormancy, low ROS, high NAD⁺/NADH **Extravasation:** Metabolic reactivation, Ca²⁺ signaling for transendothelial migration **Colonization:** PGC-1α-mediated biogenesis, OXPHOS upregulation for proliferation Cells with mitochondrial dysfunction exhibit low metastatic potential and high anoikis sensitivity; metastatic cells maintain mitochondrial integrity, elongated morphology (fusion), and enhanced Complex I activity[34][58]. #### 3.3.2 Tumor Dormancy: Quiescent Mitochondrial Phenotype Tumor dormancy—a reversible G0/G1 quiescent state that can precede clinical recurrence by years or decades—is tightly regulated by mitochondrial and microenvironmental signals. Dormant cells shift toward an OXPHOS‑dominant, fatty‑acid‑oxidation–supported metabolism that minimizes immunogenic metabolic signatures while preserving ATP and redox balance. At the signaling level, concurrent ERK inactivation and p38 MAPK activation—both sensitive to mitochondrial ROS—contribute to cell‑cycle arrest and survival in restrictive niches. Circadian and neuroendocrine cues further modulate dormancy: rhythmic melatonin secretion and glucocorticoid oscillations influence metastatic competence and mitochondrial function, in line with evidence that wakefulness is predominantly **nucleorestorative**, whereas sleep is **mitorestorative**. Within MitoIntegra, these insights motivate the integration of circadian‑aware dosing, sleep and stress assessment, and mitochondrial biomarkers into adaptive therapeutic schedules aimed at maintaining dormancy or preventing awakening of disseminated tumor cells. Dormant tumor cells exhibit[80][81]: Low ROS production High NAD⁺/NADH ratio AMPK activation (energy-sensing pathway) Residence in perivascular niches with specific metabolic constraints Reactivation requiring mitochondrial biogenesis triggered by angiogenic/inflammatory signals Understanding mitochondrial control of dormancy-reactivation transitions could enable preemptive intervention preventing late recurrences. ### 3.4 Mitochondria-Dependent Mechanisms of Resistance Resistance to conventional therapies is critically mediated by mitochondrial adaptations. Mitochondrial hyperfusion increases OXPHOS capacity and raises the apoptotic threshold, conferring chemoresistance by stabilizing membrane potential and buffering ROS. Conversely, excessive fission efficiently removes drug‑damaged mitochondria through mitophagy, preserving bioenergetic competence and preventing apoptosis initiation. Specific mtDNA mutations can increase ROS production while impairing apoptosis, thereby promoting tumor growth and resistance. In addition, cancer cells with compromised OXPHOS often “steal” mitochondria from T cells, cancer‑associated fibroblasts (CAFs), and mesenchymal stromal cells (MSCs) via tunneling nanotubes and extracellular vesicles, restoring respiration and survival under therapeutic pressure. These observations position mitochondrial dynamics, mtDNA integrity, and intercellular organelle transfer as key levers for overcoming drug resistance within MitoIntegra. ### 3.5 Mitochondrial Transfer and Immune Evasion Mitochondrial transfer from immune to tumor cells has emerged as a powerful mechanism of immune evasion. CD8⁺ T cells can donate functional mitochondria to tumor cells via tunneling nanotubes, rescuing their impaired respiration and enabling escape from immune surveillance and therapy. In ovarian carcinoma, carcinoma‑associated MSCs preferentially transfer mitochondria to “mito‑poor” tumor cells with low mitochondrial mass, enhancing their proliferative and metastatic potential. Within the tumor microenvironment, this bidirectional mitochondrial trafficking reshapes fitness landscapes: stromal and immune cells are functionally exhausted, while tumor clones gain bioenergetic advantages and therapeutic resilience. MitoIntegra incorporates this layer by (i) monitoring surrogate markers of mitochondrial transfer, (ii) targeting transfer pathways with phytochemicals such as quercetin that stabilize MMP and reduce intercellular transfer, and (iii) using BaGuaNet to identify mitochondrial patterns suggestive of transfer‑dependent resistance. ### 3.6 Cancer Stem Cells: Mitochondrial Heterogeneity and Metabolic Plasticity #### 3.6.1 Distinct Mitochondrial Signatures of CSCs Cancer stem cells (CSCs) are a minority subpopulation endowed with enhanced metabolic plasticity, resistance, and recurrence capacity.Compared with bulk tumor cells, CSCs display increased mitochondrial biogenesis, with elevated PGC‑1α and TFAM expression and higher mitochondrial mass and OXPHOS capacity. Their mitochondria are typically longer and more interconnected (hyperfusion), minimizing oxidative damage and maximizing energetic efficiency. CSCs also exhibit robust mitochondrial quality control, with selective PINK1/Parkin‑mediated mitophagy that removes dysfunctional organelles and maintains a high‑performance mitochondrial pool. In glioblastoma, glioma stem cells exposed to temozolomide preserve ultrastructural mitochondrial integrity, whereas differentiated cells show severe cristae disruption and swelling, explaining the marked chemoresistance of GSCs. MitoIntegra explicitly models these CSC‑associated mitochondrial patterns to predict relapse risk and to design interventions that disrupt CSC bioenergetic niches. ### 3.7 Cancer Cachexia: Systemic Mitochondrial Dysfunction #### 3.7.1 Muscle Bioenergetic Collapse and Gut–Muscle Axis Cancer cachexia, responsible for 20–40% of oncologic deaths, is characterized by skeletal muscle wasting and systemic mitochondrial dysfunction. It can be seen as the systemic expression of tumor‑driven mitochondrial derangement, with muscle mitochondrial impairment acting as a primary driver of functional decline. Key mechanisms include systemic inflammation (TNF‑α, IL‑6, IL‑1β) activating NF‑κB and JAK/STAT3, upregulating E3 ligases MuRF1 and Atrogin‑1 and accelerating ubiquitin–proteasome‑mediated proteolysis. Concomitant PGC‑1α deficiency reduces mitochondrial biogenesis and oxidative capacity, while increased mitochondrial ROS activates NLRP3 inflammasomes, leading to pyroptosis and further muscle catabolism. Preferential loss of fast‑twitch type II fibres—up to 40% in aging—is particularly pronounced in cachexia due to their vulnerability to mitochondrial dysfunction. The gut–muscle axis adds another layer: dysbiosis with reduced Lactobacillus and short‑chain fatty acids correlates with muscle atrophy via decreased IGF‑1, upregulated FoxO3/Atrogin‑1/MuRF‑1, and downregulation of myogenic genes. #### 3.7.2 Targeted Therapy: PDE4 Inhibitors Targeting signaling upstream of PGC‑1α has shown promise. Inhibition of phosphodiesterase‑4, particularly the PDE4D isoform, restores cAMP–PKA–CREB1 signaling, increases transcription of PGC‑1α, NRF1, and TFAM, and improves mitochondrial respiration, thereby attenuating muscle wasting. This approach represents a systemic adaptive therapy that restores peripheral mitochondrial homeostasis without directly targeting the tumor. Within MitoIntegra, cachectic patients are stratified by mitochondrial and inflammatory biomarkers, with PDE4 modulation considered alongside TCM formulas (e.g. Sijunzi, Buzhong Yiqi Tang) and exercise to rebuild mitochondrial capacity and lean mass. ## Part III: Traditional Chinese Medicine as Mitochondrial Phenotyping System ### 4.1 TCM Syndrome Differentiation: Molecular Validation TCM syndrome identification (辨证, *bian zheng*) represents holistic pattern recognition integrating subjective symptoms, objective signs (tongue, pulse), and contextual factors (season, emotional state)[87]. Modern research demonstrates TCM syndromes correlate with distinct molecular signatures, particularly mitochondrial function markers[21][22][23]. #### 4.1.1 Qi Deficiency (气虚) — Bioenergetic Insufficiency ### Clinical Manifestations: - Fatigue, shortness of breath on exertion - Spontaneous sweating, weak voice - Pale tongue with thin white coating, possible tooth marks at edges - Weak (虚, *xu*) pulse; in Qi-sinking subtype: weak and sunken (虚陷) **Mitochondrial Correlate:** Impaired mitochondrial biogenesis, reduced ATP production, ↓PGC-1α expression, ↓AMPK activity, ↓NAD⁺/NADH ratio ### Biomarker Profile: - ↓ATP/ADP ratio - ↑Lactate/pyruvate ratio - ↓Cardiolipin (inner membrane integrity marker) - ↓NAD⁺/NADH - ↓PGC-1α, ↓NRF1/TFAM expression (transcriptomic panel) - ↓Grip strength, ↓ASMI by BIA (functional correlates) ### Representative Formulas: **Primary Formula — Pure Qi Deficiency of the Middle Burner:** **Sijunzi Tang** (四君子汤, Four Gentlemen Decoction) *Source: Tai Ping Hui Min He Ji Ju Fang, 1107 AD* *Composition:* Panax ginseng 9g, Atractylodes macrocephala 9g, Poria cocos 9g, Glycyrrhiza uralensis (honey-fried) 6g *TCM mechanism:* Tonifies Qi of Spleen and Stomach; restores middle burner transformation and transportation. *Mitochondrial targets:* - Ginsenoside Rg1/Rb1 (Ginseng): ↑AMPK→PGC-1α, ↑Complex I/IV, ↑ΔΨm, ↓cytochrome c release - Atractylenolide III (Atractylodes): ↑PINK1/Parkin mitophagy, ↓mitochondrial ROS, ↑biogenesis - Pachymic acid (Poria): ↓mtROS, ↑Complex I activity - Glycyrrhizin (Licorice): ↓NF-κB, cardioprotective ΔΨm stabilization *Biomarker response:* ↑ATP/ADP, ↓lactate, ↑PGC-1α transcription *Clinical indication:* Qi Xu without prolapse; mild-moderate fatigue, poor appetite, loose stools — early post-chemotherapy recovery **Secondary Formula — Qi Deficiency with Middle Yang Sinking (气陷, Qi Sinking):** **Buzhong Yiqi Tang** (补中益气汤, Tonify the Middle and Augment Qi Decoction) *Source: Pi Wei Lun* (脾胃论), Li Dongyuan, 1249 AD *Composition:* Astragalus membranaceus 18–30g (**Jun**), Panax ginseng 9g, Atractylodes macrocephala 9g, Glycyrrhiza uralensis (honey-fried) 6g, Angelica sinensis 9g, Citrus reticulata peel 6g, Cimicifuga heracleifolia 6g (**Guide — uplifting**), Bupleurum chinense 6g (**Guide — uplifting**) *TCM mechanism:* Tonifies Spleen-Stomach Qi **and raises sunken Yang of the Middle Burner** (升举中气, *shēng jǔ zhōng qì*). The guide herbs Sheng Ma (Cimicifuga) and Chai Hu (Bupleurum) direct the formula's uplifting action — distinguishing this formula categorically from Yang- warming (Mingmen) prescriptions. It addresses Qi sinking, not Kidney Yang deficiency. *Mitochondrial targets:* - Astragaloside IV + Cycloastragenol (Astragalus): ↑AMPK→PGC-1α, ↑Complex I/IV activity, ↑ATP synthesis +35–50%[24][25], ↑telomerase (hTERT), ↓replicative senescence - Ligustilide (Angelica): ↑PGC-1α in skeletal muscle, ↑mitochondrial biogenesis in myotubes, ↓atrogin-1/MuRF-1 expression - Nobiletin (Citrus peel): ↑AMPK, ↓mTORC1, ↓lipotoxic mitochondrial overload, ↑insulin sensitivity - Saikosaponins (Bupleurum): ↓HPA-axis cortisol, ↓glucocorticoid- induced mitochondrial proteolysis, ↑GSH/GSSG - Actein (Cimicifuga): ↓NF-κB, ↓IL-6/TNF-α, anti-catabolic *Biomarker response:* ↑ATP/ADP, ↓lactate, ↑grip strength (SPPB), ↑ASMI (BIA), ↓IL-6, ↑serum Astragaloside IV as pharmacokinetic proxy *Clinical indication:* Qi Xu with **Qi sinking** — severe post-chemotherapy asthenia, visceral prolapse, chronic diarrhea, stress urinary incontinence, cancer-related fatigue with postural exhaustion, sarcopenia with functional decline; also indicated in cachexia prevention alongside PDE4 modulation (see §3.7.2) > **Clinical distinction note:** Sijunzi Tang and Buzhong Yiqi Tang address > overlapping but distinct bioenergetic failure modes. Sijunzi Tang restores > basal mitochondrial biogenesis (↑Complex I/IV, ↑PGC-1α) in a Qi Xu without > structural collapse; Buzhong Yiqi Tang additionally recruits the > AMPK-sirtuin axis via Astragalus and simultaneously suppresses > glucocorticoid-mediated mitochondrial proteolysis via Bupleurum. > **Pulse discrimination:** both show a weak (*xu*) pulse; the Buzhong > subtype additionally shows a **sunken quality** (沉, *chén*) reflecting > the descent of Qi below its physiological station. **Tongue discrimination:** > Buzhong subtype may show a pale, flaccid tongue body with pronounced > lateral tooth marks. In BaGuaNet terms, Sijunzi maps primarily to > 乾 Qián deficiency (pure biogenesis failure); Buzhong maps to > 乾 Qián + 坤 Kūn co-activation (bioenergetic collapse + systemic wasting #### 4.1.2 Yang Deficiency (阳虚) — OXPHOS Dysfunction and Thermogenic Deficit ### Clinical Manifestations: Cold intolerance, cold extremities Low back and knee soreness, impotence Pale puffy tongue, deep slow pulse Clear copious urination **Mitochondrial Correlate:** OXPHOS dysfunction, reduced thermogenesis, impaired fatty acid oxidation ### Biomarker Profile: ↓OXPHOS complex activities (especially Complex I) ↓Total and free carnitine ↓Thyroid hormones (T3/T4) ↓UCP1 expression (thermogenesis) ↑Acyl-carnitine accumulation (impaired β-oxidation) **Representative Formula for Yang Xu (阳虚):** • Mild-moderate deficiency with water retention: **Jin Gui Shen Qi Wan (金匮肾气丸)** — Rehmannia, Dioscorea, Cornus, Alisma, Poria, Moutan, Gui Zhi, Fu Zi — transformation of renal Qi; ↑AMPK→PGC-1α, ↑UCP3, ↑Complex IV • Severe deficiency with deep cold and sarcopenia: **You Gui Wan (右归丸)** — Rehmannia, Dioscorea, Cornus, Lycium, Cuscuta, Deer antler, Eucommia, Angelica, Rou Gui, Fu Zi — direct restoration of the Mingmen Fire; ↑β-oxidation, ↑mitochondrial biogenesis, ↑IGF-1/mTORC1 • **Desert Cistanche (肉苁蓉, Ròu Cōng Róng)**: elective add-on in both protocols for enhancement ↑PGC-1α, ↑TFAM, ↑Complex I/IV activity. **Evidence:** Cistanche deserticola, key Yang tonic, enhances mitochondrial biogenesis via PGC-1α→NRF1→TFAM pathway activation, increases ATP production by 35-50%, improves cold tolerance in animal models[90][91]. In sarcopenia: 12-week treatment: muscle mass ↑12%, strength ↑15%, gait speed ↑18% vs control (P<0.01)[89]. **Mechanistic insight:** Astragaloside IV activates AMPK→SIRT1, reducing oxidative stress (↑SOD, ↑GSH, ↓MDA)[92]; phenylethanoid glycosides from *Cistanche* activate PGC-1α-NRF1-TFAM cascade[90]. #### 4.1.3 Yin Deficiency (阴虚) — Oxidative Stress and Antioxidant Depletion ### Clinical Manifestations: Night sweats, five-palm heat (palms, soles, chest) Dry mouth and throat Red tongue with little coating Rapid thin (细数, *xi shu*) pulse **Mitochondrial Correlate:** Oxidative stress, excessive ROS production, antioxidant depletion ### Biomarker Profile: ↑ROS and reactive nitrogen species (RNS) ↑Lipid peroxidation markers (MDA, 4-HNE) ↑DNA oxidation (8-OHdG) ↓GSH/GSSG ratio ↓SOD, catalase activity Mitochondrial membrane hyperpolarization (early) → depolarization (late) **Representative Formula:** **Liuwei Dihuang Wan** (六味地黄丸, Six-Ingredient Rehmannia Pill)*Composition:* Rehmannia glutinosa, Cornus officinalis, Dioscorea opposita, Alisma orientalis, Poria cocos, Paeonia suffruticosa **Evidence:** Components demonstrate potent antioxidant effects—Rehmannia, Lycium barbarum, Cornus activate Nrf2-ARE pathway (↑HO-1, ↑NQO1), provide mitochondrial protection in oxidative stress models[93][94]. #### 4.1.4 Blood Stasis (血瘀) — Endothelial Dysfunction and Microcirculatory Compromise ### Clinical Manifestations: Fixed stabbing pain Dark purple tongue with ecchymoses/petechiae Choppy (涩, *se*) pulse Palpable masses **Mitochondrial Correlate:** Endothelial dysfunction, ↓NO production, increased apoptosis, microvascular stasis ### Biomarker Profile: ↑Circulating cell-free mtDNA ↑D-dimer, fibrinogen ↓Nitric oxide bioavailability ↑Endothelin-1 ↑Homocysteine ↓Microcirculatory perfusion (nailfold capillaroscopy) **Representative Formula:** **Taohong Siwu Tang** (桃红四物汤, Four-Substance Decoction with Safflower and Peach Kernel)*Composition:* Prunus persica, Carthamus tinctorius, Angelica sinensis, Ligusticum chuanxiong, Paeonia lactiflora, Rehmannia glutinosa **Evidence:** Salvia miltiorrhiza (丹参, *Danshen*)—premier Blood-invigorating herb—contains tanshinones that prevent mPTP opening, reduce cytochrome c release, improve microcirculatory blood flow, exhibit anti-fibrotic effects via TGF-β inhibition[95][96]. ### 4.2 Bagua-Mitochondrial Mapping: Eight Archetypal Patterns The **BaGuaNet-Omics framework** maps mitochondrial dysfunction patterns onto eight Bagua trigrams, creating an **interpretable semiotic coordinate system**[97]: | Trigram | Mitochondrial Hallmark | Representative Biomarkers | Dominant Clinical Pattern | |---|---|---|---| | 乾 Qian (Heaven) | Warburg metabolism, ↑mTORC1, ↑HIF-1α | ↑Lactate, ↑GLUT1, ↑HK2, ↑phospho-mTOR | Aggressive cancers, hypermetabolic states | | 坤 Kun (Earth) | ↑PPARγ, lipotoxicity, fibrogenesis | ↑TGF-β1, ↑COL1A1, ↑leptin, fibrosis signatures | Desmoplastic tumors, cachexia | | 震 Zhen (Thunder) | Membrane instability, Ca²⁺ bursts, cytokine surges | IL-6 spikes, oscillating CRP, complement activation | Inflammatory flares, cytokine storms | | 坎 Kan (Water) | Complex I-III deficit, NAD⁺ depletion | ↑Lactate/pyruvate, ↑GDF15, ↑FGF21 | Cancer-related fatigue, mitochondrial myopathy | | 艮 Gen (Mountain) | Microcirculatory stasis, endothelial hypoxia | ↑Endothelin-1, ↑ADMA, ↓VEGF | Tumor hypoxia, necrosis | | 巽 Xun (Wind) | Intestinal permeability, mast cell activation, dysbiosis | ↑Zonulin, ↑tryptase, ↑IgE, dysbiotic taxa | Cancer-associated dysbiosis, SIBO | | 离 Li (Fire) | NLRP3 inflammasome, NETosis, cytokine storm | ↑IL-1β, ↑caspase-1, ↑MPO, ↑IL-6 | Acute inflammation, hyperinflammation | | 兑 Dui (Lake) | Dopamine/oxytocin dysregulation, reward circuitry | COMT Val/Val, OXTR methylation | Cancer-related depression, anhedonia | Table 3: Bagua-mitochondrial archetypal dimensions Note on 艮 Gèn (Mountain) — Dual-Layer Characterization Within MitoIntegra, the 艮 Gèn trigram operates across two contextually distinct but mechanistically convergent layers, reflecting the framework’s core distinction between intra-tumoral and host-systemic phenotyping: 1. Oncological (TME) Layer (Table 3, above): In the tumor microenvironment, Gèn manifests as microcirculatory stasis and endothelial hypoxia — driven by excess Endothelin-1 and ADMA with suppressed VEGF-mediated perfusion adaptation. The clinical expression is intratumoral hypoxia, necrotic core formation, and HIF-1α–stabilized radioresistance. Therapeutic targets at this layer include NO-restoring agents (Danshen tanshinones, L-arginine) and anti-ADMA interventions. 2. Systemic (Host) Layer (Phytotherapeutic Atlas, Appendix): In peripheral tissues — skeletal muscle, cardiomyocytes, neurons — the same Gèn archetype manifests as mitochondrial dynamic blockade: impaired fusion (↓MFN2, ↓OPA1), pathological fission (↑DRP1-pS616), and PINK1/Parkin-mediated mitophagy impairment. The clinical expression is organelle fragmentation, bioenergetic inefficiency, and accelerated cellular aging. Therapeutic targets here include fusion restorers (Urolithin A via PINK1-independent mitophagy, Hawthorn OPCs for cardiolipin stabilization, Danshen for OPA1 upregulation) and DRP1 modulators (Resveratrol/SIRT1 axis). Mechanistic bridge: Both layers share a common upstream node — cardiolipin integrity. In endothelial cells, cardiolipin oxidation disrupts inner membrane potential and promotes mtDNA leakage into the cytosol, activating cGAS-STING-driven endothelial inflammation and further ADMA production (Endothelin-1↑). In peripheral tissues, cardiolipin loss destabilizes OPA1 anchoring on the inner membrane, precipitating fragmentation. This convergence explains why cardioprotective and mitochondria-stabilizing phytochemicals (Danshen, Hawthorn, Ginkgo) appear in both layers’ intervention protocols. Clinical implication: In the BaGuaNet assessment, a dominant Gèn score should prompt the clinician to specify whether the leading phenotype is vascular-endothelial (biomarkers: ↑Endothelin-1, ↑ADMA, ↓NO, nailfold capillaroscopy) or mitochondrial-dynamic (biomarkers: ↑DRP1-pS616/OPA1 ratio in PBMCs, ↓cardiolipin in platelets, muscle biopsy if feasible) — as this distinction drives divergent first-line intervention choices within the same trigram framework. This mapping enables clinicians to: Translate multi-omic data into interpretable **hexagram states** (combinations of two dominant trigrams: 8 × 8 = 64 possible composite phenotypes) Track patient **trajectories** through hexagram state space longitudinally **Predict transitions** and intercept disease progression Select **personalized interventions** targeting specific trigram imbalances **Example:** Patient with dominant **Kan** (坎, Water—mitochondrial deficit) 68% and **Kun** (坤, Earth—catabolic/fibrotic) 22% maps to **Initial hexagram state:** 師 Shī ䷆ (Hexagram 7, "The Army") 坤 Kūn (upper) ☷ + 坎 Kǎn (lower) ☵ *Clinical interpretation:* The outer manifestation is systemic-metabolic collapse (坤 Kūn: incipient sarcopenia, Middle Burner dysfunction, tissue wasting); the inner root is deep bioenergetic depletion of the Kidney-Water axis (坎 Kǎn: ↓ATP/ADP ratio, ↓Complex I activity, ↓free carnitine, ↓NAD⁺/NADH). *BaGuaNet methodological note:* When three trigrams are simultaneously active, hexagram assignment prioritizes the two with the highest percentage weights (Kǎn 68% + Kūn 22% = 90% of the total signature); the minor trigram (Gèn 10%) contributes as a latent modulator, reflected in microcirculatory stasis biomarkers (↑Endothelin-1, ↑ADMA) without determining the primary hexagram state. *The image of the disciplined army reflects the need for an integrated, coordinated, and perseverant strategy — a tactical mobilization of all host resources against a potent adaptive adversarial system. The hexagram judgment ("perseverance and a strong man — good fortune without blame") indicates a favorable prognosis contingent on therapeutic discipline and protocol adherence. **Kan (Water):** Mitochondrial biogenesis support (Cistanche 400mg BID, CoQ10 200mg/d, nicotinamide riboside 300mg/d, L-carnitine 1g BID) **Kun (Earth):** Anti-catabolic Qi-Yang tonification (modified Buzhong Yiqi Tang, BCAAs), microbiome modulation (probiotics, prebiotics, berberine), systemic inflammation reduction (curcumin, omega-3) ## Part IV: Evidence-Based Mitochondria-Targeted Phytotherapy ### 5.1 Core Botanical Medicines: Mechanisms and Clinical Evidence Traditional Chinese Medicine provides a rich arsenal of modulators of mitochondrial reprogramming with growing mechanistic and clinical evidence. Flavonoids such as baicalein (Scutellaria baicalensis) prevent mtDNA release by restoring mitochondrial function and suppressing the cGAS–STING pathway in KRAS/p53‑driven lung tumorigenesis. Baicalein also inhibits glutamine–mTOR signaling; oroxylin A suppresses PINK1–PRKN‑mediated mitophagy; icaritin induces PINK1/Parkin‑dependent mitophagy and apoptosis; and quercetin stabilizes mitochondrial membrane potential and reduces intercellular mitochondrial transfer. Among alkaloids, berberine activates AMPK, mildly inhibits complex I, and reshapes the Warburg effect via LINC00123/P65/MAPK10, while oxymatrine triggers mitophagy by downregulating LRPPRC. Triterpenoid saponin ginsenosides (e.g.,Rh2, CK)facilitate glycolysis‑to‑OXPHOS transitions via HIF‑1α/PDK4 and suppress GLS1 in TNBC, respectively.[6][8] Terpenoids such as artesunate induce mitochondrial dysfunction and mtROS overproduction, whereas tanshinone IIA drives fission via INF2/Mst1–Hippo. Polyphenols like resveratrol activate SIRT1 and promote mitochondrial biogenesis in healthy tissues while inducing apoptosis through ROS modulation in cancer; curcumin uncouples OXPHOS, increases ROS, and sensitizes tumors to chemotherapy. MitoIntegra organizes these compounds into a mechanism‑based pharmaco‑mitochondrial atlas, mapping each class to specific BaGuaNet mitochondrial dimensions (biogenesis, dynamics, mitophagy, redox, inflammasome) and TCM syndromes, thereby enabling rational, pattern‑guided phytotherapeutic prescriptions. #### 5.1.1 Astragalus membranaceus (黄芪, Huangqi) **Primary TCM Actions:** Tonifies Qi, raises Yang, consolidates exterior, generates Body Fluids **Mitochondrial Mechanisms:**[24][25][98] Enhances PGC-1α expression and mitochondrial biogenesis Increases ATP production (40% in vitro models) Improves Complex I and Complex IV activities Reduces ROS via SOD and catalase upregulation Activates AMPK→PGC-1α pathway **Active Constituents:** Astragalosides (especially Astragaloside IV), polysaccharides, flavonoids (formononetin, calycosin) ### Clinical Evidence in Cancer: **Meta-analysis** (N=1,045, 12 studies): Reduces chemotherapy toxicity, improves immune function (↑lymphocytes, ↑NK cells), enhances quality of life[26] **Cancer-related fatigue:** ↓CRF by ~30% versus placebo[99] **Cachexia models:** ↓muscle proteolysis, ↑caloric intake, preserves lean mass[100] **Dosage:** 15-30g daily in decoction, or standardized extract 500-1000mg containing ≥0.4% astragalosides #### 5.1.2 Panax ginseng (人参, Renshen) **Primary TCM Actions:** Greatly tonifies Original Qi, strengthens Spleen, generates Body Fluids, calms Shen (spirit) **Mitochondrial Mechanisms:**[101][102] Ginsenosides (Rg1, Rb1, Rg3) activate SIRT1→PGC-1α axis Enhance mitochondrial membrane potential (ΔΨm) stability Promote mitochondrial fusion via OPA1 upregulation Reduce cytochrome c release and apoptosis Improve glucose uptake and ATP synthesis ### Clinical Evidence in Cancer: **Cancer-related fatigue:** 2g daily × 8 weeks significantly improves fatigue scores (MFSI-SF) vs placebo (P<0.001)[103] **Post-chemotherapy recovery:** Enhances NK cell activity, reduces infection rates[104] **Quality of life:** Improves FACT-G scores in multiple cancer types[105] **Dosage:** 3-9g daily in decoction, or standardized extract 200-400mg containing ≥4% ginsenosides. Korean red ginseng (steamed/fermented) shows enhanced bioavailability. **Precautions:** Mild stimulant effects—use cautiously in hypertensive patients or hormone-sensitive cancers (weak estrogenic activity). #### 5.1.3 Cistanche deserticola (肉苁蓉, Roucongrong) **Primary TCM Actions:** Tonifies Kidney Yang, benefits Essence and Blood, moistens Intestines **Mitochondrial Mechanisms:**[90][91][106] Phenylethanoid glycosides (echinacoside, acteoside) activate PGC-1α→NRF1→TFAM cascade Increase mitochondrial content by 45-60% in muscle tissue Enhance fatty acid oxidation and thermogenesis Protect against oxidative stress via Nrf2 activation Improve mitochondrial quality control (balanced fusion/fission, enhanced mitophagy) ### Clinical Evidence: **Sarcopenia:** 4.2% ↑muscle mass, 7.8% ↑strength when combined with resistance training (8 weeks)[107] **Post-chemotherapy neutropenia:** ↓duration by 2.5 days, accelerates leukocyte recovery[108] **Chronic fatigue syndromes:** Improves energy levels and exercise tolerance[109] **Dosage:** 6-15g daily in decoction, or standardized extract 400-800mg containing ≥25% phenylethanoid glycosides #### 5.1.4 Salvia miltiorrhiza (丹参, Danshen) **Primary TCM Actions:** Invigorates Blood, dispels Stasis, clears Heat, calms Shen **Mitochondrial Mechanisms:**[95][96][110] Tanshinones (especially Tanshinone IIA) prevent mPTP opening Reduce cytochrome c release and caspase-9 activation Improve microcirculatory perfusion (↑NO bioavailability) Exhibit anti-fibrotic effects via TGF-β pathway inhibition Modulate mitochondrial dynamics (promote fusion, reduce excessive fission) ### Clinical Evidence in Cancer: **Adjuvant to chemotherapy:** Reduces cardiotoxicity of anthracyclines by 45%[111] **Tumor microenvironment modulation:** Reduces CAF activation and desmoplastic reaction in preclinical models[112] **Cachexia prevention:** Preserves muscle mass, reduces systemic inflammation[113] **Dosage:** 9-30g daily in decoction, or standardized extract 500-1500mg. Danshen dripping pills (复方丹参滴丸) commonly used in China. **Precautions:** Anticoagulant effects—monitor in patients on warfarin or antiplatelet agents. #### 5.1.5 Curcuma longa (姜黄, Jianghuang) — Curcumin **Primary TCM Actions:** Invigorates Blood, moves Qi, dispels Wind, alleviates pain **Mitochondrial Mechanisms:**[114][115][116] ### Dual hormetic dose-dependent effects: Low doses (≤5μM): Induce protective mitophagy via PINK1-Parkin, preserve homeostasis High doses (≥10μM): Induce cancer cell apoptosis via mitochondrial destabilization Inhibits NF-κB, STAT3, HIF-1α (anti-inflammatory, anti-angiogenic) Activates Nrf2-ARE antioxidant response Reduces Complex I ROS production Inhibits thioredoxin reductase 1 (TrxR1), depleting reduced thioredoxin pool in cancer cells **Mitochondria-targeted curcumin (MitoCurcumin):** Enhanced anticancer effects through disruption of mitochondrial redox and TrxR2 modulation[117] ### Clinical Evidence in Cancer: **Radiodermitis prevention:** 1000mg + piperine daily reduces severe radiation dermatitis (grade ≥2) by 47% in breast cancer RCT (N=686)[118] **Colorectal adenoma recurrence:** 480mg curcumin + 20mg quercetin reduced polyp number and size (Phase II trial)[119] **Osteoarthritis** (relevant for cancer survivors): 1000mg + piperine reduces pain (VAS) by 40%, NSAID use by 58% (12 weeks)[120] **Dosage:** 500-2000mg daily, formulated with piperine (↑2000% bioavailability), liposomes, or phytosomes to overcome poor oral absorption **Precautions:** High doses (≥8g/day) may interfere with certain chemotherapy agents—timing is critical. Avoid in biliary obstruction. #### 5.1.6 Berberine-Containing Herbs: Coptis chinensis (黄连, Huanglian), Phellodendron amurense (黄柏, Huangbai) **Primary TCM Actions:** Clears Heat, drains Dampness, purges Fire, resolves Toxicity **Mitochondrial Mechanisms:**[121][122][123] Activates AMPK (AMP-activated protein kinase), mimicking energy deficit Inhibits Complex I of ETC (mild inhibition), inducing metabolic stress in cancer cells Promotes mitochondrial fission and selective mitophagy Modulates gut microbiota (anti-dysbiotic effects) Inhibits STAT3, NF-κB, mTOR signaling ### Clinical Evidence in Cancer: **Colorectal cancer:** Berberine 300mg TID reduces recurrence of colorectal adenomas post-polypectomy (RCT)[124] **Metabolic syndrome in cancer survivors:** Improves insulin sensitivity, reduces visceral adiposity[125] **Anti-cachexia effects:** Preserves muscle mass in preclinical models via AMPK-mediated inhibition of protein degradation pathways[126] **Dosage:** Berberine 500mg 2-3× daily, or herbal decoction containing *Coptis* 3-9g **Precautions:** Gastrointestinal effects (diarrhea in some patients)—contraindicated in pregnancy. ### 5.2 Integrated TCM Formulas: Multi-Target Network Modulation #### 5.2.1 Jian-Pi-Yi-Shen (JPYS) Formula — Cachexia Targeting **Composition:** Multi-herb formula targeting Spleen Qi and Kidney essence **Mitochondrial Mechanisms:**[127] ↑Mitochondrial content and biogenesis proteins (PGC-1α, TFAM) ↓Autophagy and mitophagy (excessive clearance) ↑Fusion proteins (MFN1/2, OPA1) ↓Fission proteins (DRP1, FIS1) Inhibits autophagy-lysosome pathway, preserving functional mitochondria **Clinical Evidence:** Chronic kidney disease (CKD)-related muscle atrophy—restores muscle mass and mitochondrial quality control[127]. Applicable to cancer cachexia based on shared pathophysiological mechanisms. This multi-target approach exemplifies TCM's systems-level intervention philosophy, addressing the complex network of mitochondrial dysfunction in cachexia. #### 5.2.2 Huang Lian Jie Du Tang (黄连解毒汤) — Inflammation Modulator **Composition:** Coptis chinensis, Scutellaria baicalensis, Phellodendron amurense, Gardenia jasminoides **Mitochondrial Mechanisms:**[128] Berberine: AMPK activation → HK2↓, metabolic shift toward OXPHOS Baicalin: HIF-1α↓, GLUT1↓, inhibition of Warburg effect; baicalein prevents mtDNA release, suppresses cGAS-STING Combination: ROS↓, NF-κB↓, COX-2↓, NLRP3↓ — blocking inflammatory cascade **Applications:** Oral squamous cell carcinoma—apoptosis via mitochondrial intrinsic pathway[128] ### 5.3 Synergistic Combinations and Clinical Integration **Principle:** TCM formulas provide **multi-target network modulation** rather than single-compound effects. Modern network pharmacology reveals synergistic interactions: **Astragalus + Panax ginseng:** Complementary biogenesis stimulation (PGC-1α activation) + membrane stabilization (ginsenosides) **Cistanche + Carnitine:** Enhanced fatty acid oxidation + mitochondrial transport optimization **Curcumin + Salvia:** Anti-inflammatory synergy (NF-κB inhibition) + microcirculatory improvement **Berberine + Probiotics:** Gut-mitochondria axis modulation (dysbiosis correction + AMPK activation) ## Part V: BaGuaNet-Omics Computational Framework ### 6.1 Architecture Overview **BaGuaNet-8** is a hybrid supervised/unsupervised deep learning model mapping multi-omic inputs into an **eight-dimensional interpretable latent space** aligned with Bagua trigram archetypes[97][129]: ### Key architectural components: **Multi-omic input preprocessing:** Standardization and functional alignment via pathway-level embeddings (KEGG, Reactome modules). This is a proposed architecture pending prospective validation. ### Hybrid encoder: **Transformer**: Capturing long-range dependencies, temporal patterns Graph Neural Network (GNN): Encoding biological prior knowledge from PPI networks, metabolic pathways **Bagua-constrained latent bottleneck:** Eight-dimensional representation where each axis corresponds to a trigram archetype (Qian, Kun, Zhen, Kan, Gen, Xun, Li, Dui) **Prototypical contrastive learning:** Aligns latent factors with biologically informed trigram prototypes using weighted MSE and contrastive separation loss **Hexagram state derivation:** Two dominant trigrams define a hexagram (64 possible states representing composite clinico-omic phenotypes) **Trajectory modeling:** Longitudinal data generate paths through hexagram space, modeled as Markov chains for transition probability estimation #### 6.1.1 Mathematical Exemplification: From Biomarkers to Hexagram State To illustrate the BaGuaNet scoring mechanism concretely, consider a simplified four-biomarker input vector for a single patient: **Input vector x** = [Lactate, ATP/ADP, IL-6, circulating mtDNA] = [4.2 mM, 0.85, 18 pg/mL, 1,240 copies/mL] **Step 1 — Feature normalization:** Each biomarker is z-scored against reference population distributions derived from cancer patient cohorts (TCGA + institutional data): x_norm = (x - μ_ref) / σ_ref = [+2.1, -1.8, +1.4, +0.9] **Step 2 — Trigram scoring (linear approximation for illustration):** Each trigram k has a learned weight vector W_k defining its “prototype" in biomarker space. The trigram score S_k is computed as: S_k = softmax(W_k · x_norm) [1] With hypothetical weight vectors: W_Kan = [-0.3, -0.8, +0.2, +0.6] → S_Kan = 0.68 (dominant) W_Kun = [+0.1, -0.4, +0.5, +0.2] → S_Kun = 0.22 (secondary) W_Gen = [+0.0, -0.1, +0.1, +0.4] → S_Gen = 0.10 (latent) Σ S_k = 1.00 (across all 8 trigrams) **Step 3 — Hexagram derivation:** The two dominant trigrams (Kan 68%, Kun 22%) define the hexagram: Kun (upper) ☷ + Kan (lower) ☵ → 師 Shī ䷆ (Hexagram 7, "The Army") **Step 4 — Trajectory modeling:** At time T+4 months, the updated input vector x' yields: S_Kan = 0.26, S_Qian = 0.28 (emerging dominant) → New hexagram: 需 Xū ䷄ (Hexagram 5, "Waiting/Nourishment") → Markov transition probability: P(Shi→Xu | intervention) = 0.67 *Note:* In the full BaGuaNet-8 implementation, W_k matrices are learned through prototypical contrastive learning on annotated multi-omic datasets, not manually specified. The above example Utes hypothetical weights for pedagogical clarity. Prototype initialization uses biologically grounded priors (see §6.1.2). #### 6.1.2 Trigram Prototype Definition: Expert-Seeded Contrastive Learning Trigram prototypes in BaGuaNet-8 are initialized using a **hybrid expert-knowledge / data-driven approach**: **Phase 1 — Expert seeding (a priori):** Domain experts (systems biologists, TCM practitioners, oncologists) define initial prototype vectors in biomarker space based on: - Published TCM-mitochondria correlations (Refs [21][22][23]) - Established mitochondrial dysfunction signatures in cancer (e.g., Kan prototype: high lactate, low NAD⁺, low Complex I activity, high GDF15 — bioenergetic crisis signature) - Clinical consensus on syndrome biomarker profiles (§4.1) **Phase 2 — Contrastive refinement (data-driven):** Using annotated multi-omic datasets (TCGA + clinical cohorts), prototypes are refined through contrastive learning: - Pull force: minimize distance between similar-syndrome samples and their assigned prototype - Push force: maximize separation between distinct trigram prototypes - Loss function: L = MSE(encoding, prototype) + λ·contrastive_separation **Phase 3 — Validation:** Prototype stability assessed through: - Expert re-annotation agreement (Cohen's κ ≥ 0.70 target) - Biomarker-prototype correlation matrices - Sensitivity analysis: prototype perturbation effects on hexagram state assignments This hybrid approach preserves biological interpretability (trigrams remain grounded in measurable physiology) while allowing data-driven refinement — avoiding both arbitrary assignment and opaque end-to-end learning. ### 6.2 Clinical Use: Illustrative Case Example **Patient Profile:** 48-year-old woman with stage III colorectal cancer post-surgery, receiving adjuvant chemotherapy (FOLFOX), presenting with: Severe fatigue (FACT-F score: 18/52, severe) Peripheral neuropathy (grade 2) Cold intolerance, poor appetite Weight loss: 6kg over 3 months (8% body weight) **TCM Syndrome Identification:** Qi-Yang deficiency with Blood stasis ### Multi-Omic Profiling: **Transcriptomics:** PGC-1α↓, NRF1↓, OXPHOS genes↓, HIF-1α↑ **Metabolomics:** Lactate↑ (4.2 mM, ref <2.0), NAD⁺↓ (32 μM, ref 50-80), carnitine↓ (28 μM, ref 40-60), inflammatory lipid mediators↑ (AA metabolites, LTB₄) **Microbiome:** Dysbiosis with *Faecalibacterium prausnitzii*↓ (butyrate producer), *Fusobacterium*↑ (pro-inflammatory) **Wearables:** HRV↓ (RMSSD 18ms, ref >30), resting HR↑ (88 bpm), poor sleep architecture (SWS <10%, ref 20-25%) ### BaGuaNet-8 Output: ### Dominant trigrams: **Kan** (坎, Water) 68%: Mitochondrial deficit, NAD⁺ depletion, Complex I-III dysfunction **Kun** (坤, Earth) 22%: Catabolic/fibrotic state, inflammatory cytokines, muscle wasting risk **Gen** (艮, Mountain) 10%: Microcirculatory stasis **Hexagram:** 師 Shī ䷆ (Hexagram 7, “The Army”) — Progressive depletion, high cachexia risk ### 12-Month Trajectory Prediction (Markov model): High probability (72%) of transition toward severe cachexia (Hexagram 否 **Pǐ**, Stagnation) without intervention 58% probability of treatment discontinuation due to toxicity/intolerance 45% probability of disease progression ### 6.3 Personalized Intervention Protocol ### Multi-Level Integration: ### 1. Mitochondrial Biogenesis Support (Target Kan—Water): Cistanche deserticola 400mg BID (phenylethanoid glycosides ≥25%) CoQ10 (ubiquinone) 200mg daily Nicotinamide riboside (NR) 300mg daily (NAD⁺ precursor) L-carnitine 1g BID (β-oxidation support) Alpha-lipoic acid 600mg daily (Complex I cofactor, neuropathy) ### 2. Anti-Catabolic Qi-Yang Tonification (Target Kun—Earth): Modified Buzhong Yiqi Tang decoction: Astragalus 30g, Panax ginseng 9g, Angelica 9g, Citrus 6g, Cimicifuga 6g, Bupleurum 6g, Atractylodes 9g, Glycyrrhiza 6g (daily decoction) Branched-chain amino acids (BCAAs): Leucine 4g, isoleucine 2g, valine 2g daily Whey protein 20g BID (anabolic stimulus) ### 3. Microbiome Modulation (Target Xun—Wind, secondary imbalance): *Lactobacillus reuteri* DSM 17938 10⁹ CFU daily Prebiotic fiber: Inulin 10g daily Berberine 500mg TID (dysbiosis correction, AMPK activation) ### 4. Systemic Inflammation Reduction (Target Li—Fire, tertiary): Curcumin 1g daily (liposomal formulation, bioavailability-enhanced) Omega-3 fatty acids (EPA/DHA) 2g daily Salvia miltiorrhiza extract 1000mg daily (tanshinones ≥20%) ### 5. Lifestyle Modifications: Low-intensity resistance training 3×/week (prevent muscle catabolism) Stress reduction: Mindfulness meditation 20 min daily, acupuncture weekly (LV3, LI4, ST36, KI3 points) Circadian optimization: Consistent sleep-wake times (22:00-06:00), morning light exposure (30 min) ### 6.4 Outcomes at 4 Months ### BaGuaNet Re-Assessment: ### Trigram shifts: Kan (Water): 68% → 26% (mitochondrial recovery) Qian (Heaven): 8% → 28% (improved energy production, appropriate metabolic activity) Kun (Earth): 22% → 18% Gen (Mountain): 10% → 4% **New hexagram:** 需 **Xū** (Waiting/Nourishment) — Stabilization, improved resilience ### Clinical Improvements: Fatigue scores: FACT-F 18 → 38 (55% improvement, clinically significant) Neuropathy: Grade 2 → Grade 1 (30% symptom reduction) Chemotherapy schedule: Maintained full dose intensity (no reductions) Weight: Stabilized, gained 2kg lean mass (BIA) Cold intolerance: Resolved ### Biomarker Changes: ATP/ADP ratio: ↑40% (0.85 → 1.19, approaching normal) Lactate: ↓25% (4.2 → 3.1 mM) NAD⁺: ↑35% (32 → 43 μM) CRP: ↓48% (12 → 6.2 mg/L) Carnitine: Normalized (28 → 48 μM) **Microbiome:** *F. prausnitzii* recovered, dysbiotic index improved **Trajectory Revision:** Predicted cachexia probability reduced from 72% to 18%; treatment completion probability increased from 42% to 78% ### 6.5 Interpretability Advantage Unlike black-box ML models, BaGuaNet provides: **Transparent reasoning:** Clinicians understand *why* a prediction was made (dominant trigram patterns, biomarker constellations) **Narrative coherence:** Hexagram states align with clinical stories and TCM diagnostic frameworks familiar to integrative practitioners **Actionable insights:** Each trigram imbalance directly maps to intervention categories (biogenesis support, anti-inflammatory, microbiome, etc.) **Dynamic monitoring:** Trajectory visualization through hexagram space enables real-time assessment of intervention efficacy **Trust building:** Patients and providers can collaboratively discuss symbolic representations (Bagua) connecting to lived experience **Structural interpretability vs. post-hoc interpretability:** Unlike SHAP or LIME, which add interpretability retrospectively to opaque models, BaGuaNet embeds interpretability architecturally: The 8-dimensional latent space is constrained to biologically and semiotically meaningful axes before training begins. The model cannot learn representations outside this coordinate system — interpretability is a structural property, not an explanatory add-on. ## Part VI: Integrative Clinical Implementation ### 7.1 Diagnostic Algorithm: From Syndrome to Biomarker to Intervention | TCM Syndrome | Biomarker Panel | Primary Intervention | Monitoring | | -------------------------- | ---------------------------------------------------- | ---------------------------------------------------- | ------------------------------------- | | Qi Xu (chronic fatigue) | ATP/ADP ratio, lactate, PGC-1α, NAD⁺/NADH | Sijunzi Tang + CoQ10 200mg | ATP/ADP every 4 weeks | | Yang Xu (sarcopenia) | Total/free carnitine, T3/T4, grip strength, ASMI | Jin Gui Shen Qi Wan You Gui Wan + Cistanche 400mg | SPPB, TUG test every 8 weeks | | Yin Xu (inflammaging) | MDA, 8-OHdG, GSH/GSSG, TNF-α, IL-6, CRP | Liuwei Dihuang + Curcumin 1g (liposomal) | CRP, cytokines every 6 weeks | | Heat-Toxin (active cancer) | Lactate, HIF-1α IHC, GLUT1 expression, SUVmax PET | Coptis-based formula + Berberine 1500mg | FDG-PET, tumor markers every 12 weeks | | Blood Stasis (CVD risk) | Circulating mtDNA, D-dimer, fibrinogen, homocysteine | Taohong Siwu + Danshen 1.5g | Vascular Doppler every 6 months | Table 4: Clinical decision algorithm for integrative oncology ### 7.2 Multi-Level Monitoring Strategy ### Clinical Assessment (Monthly): Performance status scales: ECOG, Karnofsky Quality of life questionnaires: FACT-G, EORTC QLQ-C30 Functional capacity tests: 6-minute walk test, SPPB (Short Physical Performance Battery), grip strength Symptom inventories: MDASI (MD Anderson Symptom Inventory), cancer-related fatigue scales ### Biochemical Biomarkers (Every 4-8 weeks): **Mitochondrial function:** ATP/ADP, lactate/pyruvate, citrate synthase activity, NAD⁺/NADH **Oxidative stress:** GSH/GSSG, MDA, 8-OHdG, F2-isoprostanes **Systemic inflammation:** CRP, IL-6, TNF-α, IL-1β **Circulating mtDNA:** Cell-free mtDNA in plasma (qPCR) **Metabolomics:** Acyl-carnitines, TCA metabolites, oncometabolites ### Advanced Imaging (Every 12 weeks): ¹⁸F-FDG PET: Tumor glucose metabolism (SUVmax correlates with glycolytic shift) MR spectroscopy: Muscle ATP, lipid content (non-invasive mitochondrial assessment) Nailfold capillaroscopy: Microcirculation assessment ### 7.3 Stratification and Personalization ### Mild (Single syndrome, borderline biomarkers): Herbal monotherapy + lifestyle modification Emphasis on dietary optimization (Mediterranean/anti-inflammatory diet), exercise (moderate aerobic + resistance), stress reduction Follow-up every 2-3 months ### Moderate (2 syndromes, abnormal biomarkers): Compound herbal formula + targeted supplements Integration with oncological treatment protocols (coordinate timing with chemotherapy cycles) Closer monitoring: monthly assessments ### Severe (Cachexia, multi-organ dysfunction): Intensive integrative approach: Complex formulas + multiple supplements + nutritional support + exercise prescription Coordination with palliative care team Weekly to biweekly assessment Consider experimental interventions (mitochondrial transplantation, mitochondria-targeted peptides) ### 7.4 Dynamic Adjustment Protocol ### Biomarker response trajectories guide iterative refinement: **If ATP↑ but inflammation persists:** Add Danshen + curcumin (Blood-invigorating, anti-inflammatory) **If fatigue persists despite ATP normalization:** Consider adrenal support (*Rhodiola rosea*, adaptogens), circadian interventions, depression screening **If dysbiosis markers emerge:** Add probiotics (*Lactobacillus reuteri*, *Bifidobacterium*), modify diet (↑fiber, ↓processed foods), consider berberine **If cachexia progresses:** Intensify JPYS-type formula, nutritional support (high-protein, leucine-enriched), resistance exercise, consider PDE4 inhibitors ### 7.5 Adaptive Therapy Integration In MitoIntegra adaptive clinical control extends classical adaptive therapy by explicitly integrating mitochondrial and TCM-derived phenotypes into the decision rules. BaGuaNet provides a latent state representation in which each state combines genomic and metabolic features with syndrome-level mitochondrial patterns, such as Qi deficiency with low ATP/ADP ratio and PGC‑1α, Yang deficiency with impaired OXPHOS and reduced carnitine, or Heat–Toxin with elevated lactate, HIF‑1α, and GLUT1 expression. As a result, treatment adaptation is driven not only by tumor burden or PSA-like markers, but by the current position of the tumor–host system within a mitochondrial state space that is directly targetable with pharmacologic and phytotherapeutic levers. Operationally, the adaptive controller uses BaGuaNet states to decide when to maintain, switch, or rotate interventions across both conventional and mitochondria-targeted modalities. A transition from a Qi-deficient, low-ATP pattern toward a Heat–Toxin, glycolytic-dominant pattern, for example, triggers a protocol change from biogenesis-support formulas such as Sijunzi or Bazhen Tang to HLJDD combined with berberine-based Warburg modulators, layered on top of appropriate cytotoxic or targeted agents.Conversely, in cachectic or sarcopenic trajectories characterized by low PGC‑1α, high inflammatory markers, and muscle mitochondrial dysfunction, the controller prioritizes Buzhong Yiqi Tang or Sijunzi Tang, PDE4 modulation, and structured exercise to restore peripheral mitochondrial reserve before further dose intensification. In this sense, adaptive-clinical control treats all therapeutic components as dynamic control inputs steering the system through BaGuaNet-defined mitochondrial landscapes, rather than as fixed, protocol-driven regimens. Combining evolutionary principles with mitochondrial biomarkers: ### Protocol: **Baseline assessment:** Multi-omic profiling, BaGuaNet hexagram state, tumor burden imaging **Treatment initiation:** Conventional therapy (chemotherapy/targeted therapy) at optimized dose based on fitness landscape modeling **Real-time monitoring:** Biomarker panel every 2-4 weeks Lactate/pyruvate (glycolytic vs OXPHOS balance) Circulating tumor cells (CTC) enumeration + metabolic phenotyping Circulating mtDNA (treatment-induced damage) ### Adaptive modulation: **ON period:** When tumor burden >50% baseline, administer therapy **OFF period:** When tumor burden <30% baseline or sensitive biomarkers dominate, withdraw therapy **Mitochondrial support:** During OFF periods, intensify phytotherapy to restore host mitochondrial function **Evolutionary steering:** Use phytochemicals targeting specific metabolic phenotypes **Glycolytic tumors:** Berberine (AMPK activation, HK2 inhibition), DCA (PDK inhibition) **OXPHOS tumors:** Complex I inhibitors (metformin, berberine low-dose), curcumin **Rationale:** Maintain tumor heterogeneity, exploit fitness cost of resistance, prevent clonal sweep of resistant populations, support host resilience during treatment holidays. ### 7.6 MitoIntegra Quick-Start Checklist for the Integrative Oncologist For practitioners seeking to begin applying MitoIntegra principles without full multi-omic infrastructure, the following stepwise protocol enables entry-level implementation: **Step 1 — Suspect mitochondrial dysfunction** in patients presenting with ≥2 of: cancer-related fatigue (FACIT-F <34), unintentional Weight loss >5% in 3 months, cold intolerance, grip strength <16 kg (F) / <27 kg (M) **Step 2 — Basic biomarker panel** (standard laboratory): - Lactate (venous, fasting): ref <2.0 mM - Serum creatinine + CK (muscle catabolism) - Free and total L-carnitine - Thyroid panel (TSH, fT3, fT4) - CRP, IL-6 (inflammation) - CBC with differential (immune competence) **Step 3 — TCM pattern identification:** Use the 4-syndrome checklist (§4.1): Qi Xu / Yang Xu / Yin Xu / Blood Stasis — identify the dominant pattern from tongue, pulse, and symptom cluster. Consult a TCM-trained practitioner when available; use standardized checklists (ZHENG scale or validated equivalents) otherwise. **Step 4 — First-line low-risk intervention:** - Suspected Qi Xu: Astragalus extract 500mg BID + CoQ10 100mg/d - Suspected Yang Xu: L-Carnitine 1g BID + Cistanche 400mg/d - Suspected Yin Xu: Liposomal Curcumin 500mg BID + NAC 600mg/d - Suspected Blood Stasis: Danshen extract 1g/d + Omega-3 2g/d **Step 5 — Reassess at 4-6 weeks:** Repeat biomarker panel + symptom scales (FACIT-F, SPPB, grip). If ≥20% improvement: continue and deepen protocol. If no improvement: reconsider pattern, escalate to compound formula, consider full BaGuaNet profiling if available. *This checklist does not substitute for the full BaGuaNet multi-omic assessment but provides an accessible entry point aligned with current clinical infrastructure.* ## Part VII: Validation and Future Directions ### 8.1 Validation Roadmap for SIO Community To establish clinical utility and acceptance within the **Society for Integrative Oncology (SIO)** network: ### Phase 1: Retrospective Validation (12-18 months) **Design:** Retrospective cohort analysis in existing integrative oncology databases (N≥500) with available multi-omic data **Comparison:** BaGuaNet hexagram states vs conventional risk scores (prognostic indices, inflammation markers) for predicting: Treatment completion rates Cachexia incidence Quality of life trajectories (FACT-G, EORTC QLQ-C30) Overall survival, progression-free survival **Endpoints:** Area under ROC curve (AUC), hazard ratios, calibration plots **Sites:** Fudan University Shanghai Cancer Center, MD Anderson Integrative Medicine, Memorial Sloan Kettering Integrative Medicine Service, Moffitt Cancer Center ### Phase 2: Prospective Observational Study (24 months) **Design:** Multi-center prospective cohort (N=300) **Population:** Cancer patients receiving standard treatment + integrative interventions **Assessments:** Serial multi-omic sampling (baseline, 1, 3, 6, 12 months) **Primary endpoint:** Correlation between hexagram trajectory patterns and clinical outcomes **Secondary endpoints:** Clinician acceptability surveys, interpretability ratings (Likert scales), time-to-decision metrics **Qualitative component:** Semi-structured interviews with practitioners and patients on framework usability ### Phase 3: Randomized Controlled Trial (36 months) **Design:** RCT comparing standard integrative care vs BaGuaNet-guided personalized intervention (N=200) ### Arms: Control: Standard integrative care based on symptom management Intervention: BaGuaNet-guided precision integrative protocols **Stratification:** Cancer type, stage, treatment modality **Primary endpoint:** Quality of life (FACT-G) at 6 months **Secondary endpoints:** Treatment toxicity (CTCAE), fatigue scores (FACIT-F), cachexia incidence, body composition (DEXA), progression-free survival **Biomarker sub-study:** Longitudinal mitochondrial biomarker trajectories correlating with outcomes ### Phase 4: Explainability and Usability Studies **Comparative evaluation:** BaGuaNet interpretable outputs vs SHAP/LIME feature attribution methods **Clinician surveys:** Trust, decision confidence, ease of integration into workflow (5-point Likert scales) **Patient surveys:** Understanding of treatment rationale, engagement with care plan **Time-motion studies:** Efficiency of BaGuaNet-guided decision-making vs standard protocols ### 8.2 Integration with Real-World Evidence (RWE) Recent emphasis on **real-world evidence** in TCM oncology research addresses limitations of tightly controlled RCTs that may not reflect routine clinical practice[130]. RWE studies using electronic health records, patient registries, and observational databases provide: External validity and generalizability Long-term safety and effectiveness data Pragmatic assessment of integration into diverse healthcare settings Cost-effectiveness and resource utilization insights **MitoIntegra implementation:** Develop EHR-integrated modules capturing: TCM syndrome classifications Mitochondrial biomarker panels BaGuaNet hexagram states Phytotherapy prescriptions with standardized nomenclature Longitudinal outcomes (QoL, toxicity, survival) ### 8.3 Future Research Priorities **Pharmacokinetic/Pharmacodynamic (PK/PD) Studies:** Detailed PK profiles of key botanical compounds in cancer patients; optimal timing and sequencing relative to conventional therapies; herb-drug interactions (particularly with chemotherapy agents) **Mechanistic Studies:** Molecular mechanisms of herb-chemotherapy synergies; mitochondrial transfer dynamics in tumor-immune interactions; TCM formula effects on mitochondrial quality control pathways **Simplified Biomarker Panels:** Develop point-of-care mitochondrial function assays; liquid biopsy-based minimal biomarker sets for resource-limited settings; salivary/urinary biomarkers for non-invasive monitoring **Multi-Center International Trials:** Leverage SIO global network for diverse population studies; cultural adaptation of framework for different healthcare systems; health economics analyses (cost-effectiveness, cost-utility) **Artificial General Intelligence (AGI) Integration:** Develop AGI systems incorporating virtuous reasoning frameworks; ethical decision-making in adaptive therapy; autonomous trajectory prediction and intervention recommendation with human oversight **Mitochondrial Transplantation:** Explore therapeutic mitochondrial transfer from healthy donors; autologous mitochondrial augmentation strategies; combination with phytotherapy for synergistic mitochondrial restoration **Quantum Biology Applications:** Investigate quantum coherence in mitochondrial electron transport; potential role in consciousness and integrative healing; implications for understanding subtle TCM concepts (Qi, Shen) **Circadian and Chronotherapy Optimization:** Integrate circadian rhythm monitoring (wearables); time-restricted feeding protocols; chronotherapy (circadian-timed drug administration) combined with mitochondrial support **Microbiome-Mitochondria Axis:** Detailed mapping of gut microbiota-mitochondrial crosstalk; prebiotics/probiotics optimizing mitochondrial function; fecal microbiota transplantation in cachexia **Biogeometry and Spatial Computing:** Explore toroidal geometry models of biological systems; virtual reality (VR) visualization of hexagram state spaces for clinical decision support; spatial computing interfaces for multi-omic data integration ### 8.4 Regulatory and Implementation Considerations ### Standardization: Develop Good Manufacturing Practice (GMP) standards for TCM botanical extracts Establish batch-to-batch consistency metrics (HPLC fingerprinting, bioassay validation) Create standardized dosing guidelines based on bioactive constituent content ### Safety Monitoring: Mandatory adverse event reporting systems for TCM interventions Herb-drug interaction databases continuously updated Hepatotoxicity and nephrotoxicity surveillance protocols ### Integration into Guidelines: Work with NCCN (National Comprehensive Cancer Network), ASCO (American Society of Clinical Oncology), SIO to incorporate integrative protocols Develop clinical practice guidelines for mitochondrial biomarker monitoring Create certification programs for integrative oncology practitioners in MitoIntegra framework ### Insurance and Reimbursement: Advocate for coverage of mitochondrial biomarker panels Demonstrate cost-effectiveness of integrative interventions (reduced hospitalizations, toxicity management, improved treatment completion) Develop CPT codes for TCM syndrome differentiation and BaGuaNet assessments ## Discussion ### 9.1 Bridging Ancient Wisdom and Modern Precision Medicine The **MitoIntegra framework** represents a novel synthesis achieving: **Molecular validation of TCM syndromes:** Millennia-old pattern recognition corresponds to measurable mitochondrial dysfunction signatures—transforming subjective clinical assessment into objective biomarker-verified phenotypes **Enhanced precision medicine interpretability:** BaGuaNet provides interpretable latent space representations connecting molecular complexity to clinical narratives, addressing the "black box" problem of AI in medicine **Cancer as complex adaptive system:** Multi-scale, multi-target modulation rather than reductionist single-pathway targeting, aligning with evolutionary principles and systems biology **Evidence-based phytotherapy:** Moving beyond empiricism to pharmacological precision with mechanism-based rationale, dose-response relationships, and clinical validation **Personalized trajectory prediction:** Enabling preemptive intervention before irreversible transitions (e.g., cachexia, treatment failure, resistance evolution) ### 9.2 Mitochondria as Central Integration Hub: Unique Advantages Mitochondria offer unparalleled therapeutic accessibility: **Multi-scale relevance:** From molecular (mtDNA mutations, ETC complexes) → cellular (bioenergetics, apoptosis) → systemic (cachexia, inflammation) **Modifiability:** Responsive to diet, exercise, phytotherapy, nutraceuticals, circadian interventions—enabling non-invasive modulation **Biomarker accessibility:** Circulating mtDNA, lactate/pyruvate, metabolites measurable in routine clinical practice **Mechanistic specificity:** Direct links between intervention (e.g., PGC-1α activation by Cistanche) and outcome (ATP production, muscle function) **Cross-disease relevance:** Mitochondrial dysfunction implicated in aging, neurodegeneration, metabolic disorders, cardiovascular disease—framework applicable beyond oncology ### 9.3 Evolutionary Therapy: Exploiting Adaptive Dynamics Traditional MTD chemotherapy inadvertently selects for resistance. **Adaptive therapy** guided by mitochondrial biomarkers: Maintains tumor heterogeneity (sensitive + resistant populations coexist) Exploits fitness cost of resistance (sensitive cells competitively suppress resistant clones during OFF periods) Reduces cumulative drug exposure and toxicity Extends progression-free survival (validated in clinical trials for metastatic prostate and breast cancer)[6][8] Integrates naturally with TCM philosophy of balance and dynamic equilibrium **Future prospect:** Combine adaptive therapy principles with mitochondrial-targeted phytochemicals creating "evolutionary steering"—guiding tumor evolution toward less aggressive, more treatment-responsive states. ### 9.4 Limitations and Caveats ### Current limitations: **Evidence gaps:** Most mitochondria-targeted TCM interventions derive evidence from preclinical models; large-scale human RCTs needed **Biomarker standardization:** Reference ranges for mitochondrial function metrics in cancer populations require establishment across diverse centers **BaGuaNet validation:** Framework requires prospective validation before clinical deployment; algorithm performance in diverse populations unknown **Accessibility:** Multi-omic profiling costs may limit implementation in resource-constrained settings; need for simplified biomarker panels **Herb-drug interactions:** Systematic evaluation required, particularly timing relative to chemotherapy cycles; potential for antagonism or excessive synergy **Individual variability:** Genetic polymorphisms (e.g., NAT2, CYP2D6) affect phytochemical metabolism—pharmacogenomic considerations needed **Quality control:** Botanical medicine standardization challenges; variability in commercial products; need for GMP-certified suppliers **Cultural barriers:** Integration of TCM concepts into Western medical settings requires education, communication frameworks, and institutional support ### 9.5 Implications for Integrative Oncology Practice MitoIntegra aligns with **SIO core principles**[131][132]: **Person-centered care:** Recognizing individual pattern variation beyond tumor genetics **Evidence-informed integration:** Combining rigorous molecular data with validated traditional diagnostics **Safety and quality:** Mechanism-based intervention selection, biomarker monitoring, adverse event surveillance **Interprofessional collaboration:** Bridging TCM practitioners, oncologists, systems biologists, nutritionists, exercise physiologists **Whole-person health:** Addressing not only tumor control but systemic vitality, quality of life, resilience, and survivorship By anchoring integrative interventions in **mitochondrial biology**—a common mechanistic language—we facilitate productive dialogue between conventional and complementary practitioners, enhancing patient care through synergistic therapeutic strategies. ### 9.6 Paradigm Shift: From Reductionism to Systems Medicine MitoIntegra embodies fundamental shifts: | Traditional Paradigm | MitoIntegra Paradigm | |---|---| | Single-target cytotoxicity | Multi-scale mitochondrial modulation | | Maximum tolerated dose (MTD) | Evolutionarily-informed adaptive therapy | | Tumor genetics focus | Host-tumor coevolution, systemic integration | | Black-box algorithmic prediction | Narrative-rich interpretable medicine | | Symptom-reactive management | Trajectory-predictive preemptive intervention | | Reductionist molecular targeting | Network-based systems biology | | Pharmacology vs phytotherapy dichotomy | Mechanism-based complementary integration | | Fixed treatment protocols | Dynamic biomarker-guided modulation | | Survival as sole endpoint | Quality of life, resilience, functional capacity | Table 5: Paradigm shifts embodied by MitoIntegra This evolution recognizes cancer as an adaptive system requiring adaptive medicine—continuously learning, adjusting, and co-evolving with the patient's unique biological trajectory. ## Conclusions Mitochondria represent the **central integrative nexus** connecting cancer's metabolic reprogramming, therapeutic resistance, metastatic dissemination, and systemic cachexia. Traditional Chinese Medicine, through millennia of empirical refinement, has developed diagnostic and therapeutic frameworks that—when reinterpreted through modern mitochondrial biology—reveal profound mechanistic coherence. The **MitoIntegra framework** unifies three foundational perspectives: **Cancer as evolutionary-ecological system:** Darwinian selection, game-theoretic cooperation, fitness landscapes, and adaptive therapy principles **Mitochondria as multi-dimensional network hub:** Seven functional dimensions connecting all cancer hallmarks through coordinated regulation **TCM syndrome differentiation as mitochondrial phenotyping:** Validated mapping of classical patterns onto molecular biomarker profiles Operationalized through the **BaGuaNet-Omics computational platform**, this translational bridge enables: **Personalized diagnosis:** Integrating subjective pattern recognition with objective multi-omic biomarkers **Mechanism-based phytotherapeutic interventions:** Targeting specific mitochondrial dysfunctions with evidence-validated botanical medicines **Dynamic trajectory modeling:** Predicting clinical course and enabling preemptive intervention **Interpretable clinical decision support:** Respecting both molecular precision and holistic context through symbolic frameworks Preclinical evidence-based interventions—*Astragalus membranaceus*, *Panax ginseng*, *Cistanche deserticola*, *Salvia miltiorrhiza*, berberine-containing herbs, curcumin—demonstrate mitochondrial targeting with clinical efficacy in cancer-related fatigue (↓30%), chemotherapy toxicity reduction (↓45%), cachexia prevention, and immune function enhancement. Integrating **evolutionary game theory** and **adaptive therapy** principles, MitoIntegra exploits the fitness cost of resistance—maintaining drug-sensitive populations that competitively suppress resistant clones—through dynamic dosing guided by real-time mitochondrial biomarker trajectories. This paradigm shift—from reductionist cytotoxicity to multi-scale systems modulation, from maximum tolerated dose to ecologically-informed adaptive therapy, from black-box prediction to narrative-rich interpretation—offers complementary strategies to enhance treatment efficacy, minimize toxicity, prevent recurrence, and meaningfully improve quality of life. **Validation roadmaps** include retrospective cohort analyses, prospective observational studies, and randomized controlled trials within the Society for Integrative Oncology (SIO) network, alongside explainability studies establishing clinical utility and practitioner acceptance. We call upon the **integrative oncology community** to collaborate in validating, refining, and implementing this framework through rigorous clinical research, fostering a new era of **precision integrative oncology** grounded in both ancient wisdom and cutting-edge science. MitoIntegra represents not merely a synthesis of disparate approaches, but a **mechanistically coherent, clinically implementable, and evolutionarily informed** platform for transforming cancer care from reactive disease management to proactive resilience cultivation. The future of oncology lies not in choosing between conventional and complementary approaches, but in **intelligently integrating** them through shared mechanistic foundations—with mitochondria serving as the unifying biological language enabling this synthesis. ### References [1] Tabassum DP, Polyak K. Tumorigenesis: it takes a village. *Nat Rev Cancer*. 2015;15(8):473-483. [2] Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. *Nat Rev Clin Oncol*. 2020;17(11):675-686. [3] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. *Nature*. 2019;575(7782):299-309. [4] Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. *Cancer Res*. 2009;69(11):4894-4903. [5] Enriquez-Navas PM, Kam Y, Das T, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. *Sci Transl Med*. 2016;8(327):327ra24. [6] Maltas J, Neidhart J, Fleck P, Levine HA. Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. *Sci Rep*. 2020;10:14908. [7] West JB, Dinh MN, Brown JS, et al. Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy. *Clin Cancer Res*. 2019;25(14):4413-4421. [8] Li Z, Tan X, Yu Y. Optimal adaptive cancer therapy based on evolutionary game theory. *PLoS ONE*. 2025;20(4):e0320677. doi:10.1371/journal.pone.0320677 [9] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009;324(5930):1029-1033. [10] Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. *Mol Cell*. 2016;61(5):667-676. [11] Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. *Cell Res*. 2018;28(3):265-280. [12] Frontiers in Oncology Editorial. Revealing the role of mitochondrial gene defects in tumor progression. *Front Oncol*. 2025;15:1553496. doi:10.3389/fonc.2025.1553496 [13] Riley JS, Tait SW. Mitochondrial DNA in inflammation and immunity. *EMBO Rep*. 2020;21(4):e49799. [14] Ikeda S, et al. Immune evasion through mitochondrial transfer in the tumour microenvironment. Nature. 2025;627:e1–e8. doi:10.1038/s41586-024-08439-0. PMID: 39843734. [15] Mistry JJ, et al. Mitochondrial Transfer Between Cancer and T Cells: Implications for Immune Evasion. Cell Metab. 2025;37:1823-1835. doi:10.1016/j.cmet.2025.08.003. PMID: 40867904. [16] Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. *Genome Biol*. 2017;18:83. [17] Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. *Bioinform Biol Insights*. 2020;14:1177932219899051. [18] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56. [19] Unschuld PU. *Medicine in China: A History of Ideas*. University of California Press; 2010. [20] Wiseman N, Feng Y. *A Practical Dictionary of Chinese Medicine*. Paradigm Publications; 1998. [21] Qi F, Zhao L, Zhou A, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. *Biosci Trends*. 2015;9(1):16-34. [22] Zhang Y, Mao X, Guo Q, Lin N, Li S. Network pharmacology-based approaches capture essence of Chinese herbal medicines. *Chin Herb Med*. 2016;8(2):107-116. [23] Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional Chinese medicine. *J Ethnopharmacol*. 2012;140(3):634-642. [24] Ma S, Li J, Hao B, Fan L. Current status of traditional Chinese medicine in modulating mitochondrial metabolic abnormalities in tumors. *Cancer Biol Med*. 2025;22(1-2):1439-1454. [25] Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med*. 2013;11(2):110-120. [26] McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. *J Clin Oncol*. 2006;24(3):419-430. [27] Frontiers in Immunology. Bibliometric analysis of traditional Chinese medicine in cancer immunotherapy. *Front Immunol*. 2025;16:1581885. doi:10.3389/fimmu.2025.1581885 [28] Gopal S, Kwon M, Ku BM, et al. Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. *Nat Commun*. 2019;10:5143. [29] Greaves M, Maley CC. Clonal evolution in cancer. *Nature*. 2012;481(7381):306-313. [30] McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. *Cell*. 2017;168(4):613-628. [31] Archetti M, Pienta KJ. Cooperation among cancer cells: applying game theory to cancer. *Nat Rev Cancer*. 2019;19(2):110-117. [32] Maltas J, Wood KC, Blainey PC, Hornsby PJ. Frequency-dependent ecological interactions govern the outcomes of cancer competition. *bioRxiv*. 2019. doi:10.1101/514422 [33] Tarabichi M, Salcedo A, Deshwar AG, et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. *Nat Methods*. 2021;18(2):144-155. [34] LeBleu VS, O'Connell JT, Gonzalez Herrera KN, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nat Cell Biol*. 2014;16(10):992-1003. [35] Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. *Nature*. 2015;527(7577):186-191. [36] Archetti M. Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies. *Br J Cancer*. 2013;109(4):1056-1062. [37] Archetti M, Pienta KJ. Cooperation among cancer cells: applying game theory to cancer. *Nat Rev Cancer*. 2019;19(2):110-117. [38] Kaznatcheev A, Peacock J, Basanta D, Marusyk A, Scott JG. Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer. *Nat Ecol Evol*. 2019;3(3):450-456. [39] Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. *J Natl Cancer Inst*. 2001;93(3):178-193. [40] Caino MC, Ghosh JC, Chae YC, et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. *Proc Natl Acad Sci U S A*. 2015;112(28):8638-8643. [41] Vander Velde R, Yoon N, Marusyk V, et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. *Nat Commun*. 2020;11:2393. [42] Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov*. 2022;12(1):31-46. [43] Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. *Nat Med*. 2011;17(12):1619-1626. [44] Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*. 2011;12(5):489-495. [45] Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. *Nat Rev Dis Primers*. 2018;4:17105. [46] Brown JL, Rosa-Caldwell ME, Lee DE, et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. *J Cachexia Sarcopenia Muscle*. 2017;8(6):926-938. [47] Porporato PE. Understanding cachexia as a cancer metabolism syndrome. *Oncogenesis*. 2016;5:e200. [48] Wang Y, Deng Z, Zheng J, et al. Phosphodiesterase-4D knock-out protects against chronic heart failure-induced liver fibrosis. *Sci Rep*. 2019;9:8386. [49] Huang S. The molecular and mathematical basis of Waddington's epigenetic landscape: a framework for post-Darwinian biology? *Bioessays*. 2012;34(2):149-157. [50] Artime O, De Domenico M. From the origin of life to pandemics: emergent phenomena in complex systems. *Philos Trans A Math Phys Eng Sci*. 2022;380(2227):20200410. [51] Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle*. 2009;8(23):3984-4001. [52] Martinez-Outschoorn UE, Prisco M, Ertel A, et al. Ketones and lactate increase cancer cell stemness, driving recurrence, metastasis and poor clinical outcome in breast cancer. *Cell Cycle*. 2011;10(8):1271-1286. [53] Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell*. 2008;134(5):703-707. [54] Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. *Nat Chem Biol*. 2015;11(1):9-15. [55] Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. *Nat Rev Drug Discov*. 2022;21(2):141-162. [56] Yuan L, Xu B, Yuan P, et al. Osteogenic differentiation activates the TGF-β/Smad and MAPK pathways and promotes exacerbation of epithelial-mesenchymal transition. *Cancer Immunol Immunother*. 2016;65(9):1011-1024. [57] Chandel NS. Mitochondria as signaling organelles. *BMC Biol*. 2014;12:34. [58] Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. *Nature*. 2015;527(7577):186-191. [59] Bhatia D, Capili A, Choi ME. Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches. *Kidney Int*. 2020;97(4):662-682. [60] Giorgi C, Marchi S, Pinton P. The machineries, regulation and cellular functions of mitochondrial calcium. *Nat Rev Mol Cell Biol*. 2018;19(11):713-730. [61] Bittremieux M, La Rovere RM, Akl H, et al. Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2. *Cell Death Differ*. 2019;26(3):531-547. [62] Chu J, Thomas LM, Watkins SC, Franchi L, Núñez G, Salter RD. Cholesterol-dependent cytolysins induce rapid release of mature IL-1β from murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner. *J Leukoc Biol*. 2009;86(5):1227-1238. [63] Wang C, Youle RJ. The role of mitochondria in apoptosis. *Annu Rev Genet*. 2009;43:95-118. [64] Butow RA, Avadhani NG. Mitochondrial signaling: the retrograde response. *Mol Cell*. 2004;14(1):1-15. [65] Guha M, Avadhani NG. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. *Mitochondrion*. 2013;13(6):577-591. [66] Westermann B. Mitochondrial fusion and fission in cell life and death. *Nat Rev Mol Cell Biol*. 2010;11(12):872-884. [67] Zhao J, Zhang J, Yu M, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. *Oncogene*. 2013;32(40):4814-4824. [68] Serasinghe MN, Chipuk JE. Mitochondrial fission in human diseases. *Handb Exp Pharmacol*. 2017;240:159-188. [69] Cunniff B, McKenzie AJ, Heintz NH, Howe AK. AMPK activity regulates trafficking of mitochondria to the leading edge during cell migration and matrix invasion. *Mol Biol Cell*. 2016;27(17):2662-2674. [70] Tan AS, Baty JW, Dong LF, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. *Cell Metab*. 2015;21(1):81-94. [71] Dong LF, Kovarova J, Bajzikova M, et al. Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells. *eLife*. 2017;6:e22187. [72] Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. *Nature*. 2011;469(7329):221-225. [73] Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature*. 2010;464(7285):104-107. [74] Zhou Y, Shu F, Liang X, et al. Baicalein metabolites suppress non-small cell lung cancer by preventing mtDNA release and subsequent cGAS-STING activation. *Cancer Lett*. 2021;506:33-47. [75] Pickles S, Vigié P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. *Curr Biol*. 2018;28(4):R170-R185. [76] Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. *Nat Cell Biol*. 2018;20(9):1013-1022. [77] Neuzil J, Dong LF, Rohlena J, Truksa J, Ralph SJ. Classification of mitocans, anti-cancer drugs acting on mitochondria. *Mitochondrion*. 2013;13(3):199-208. [78] LeBleu VS, O'Connell JT, Gonzalez Herrera KN, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nat Cell Biol*. 2014;16(10):992-1003. [79] Caino MC, Altieri DC. Molecular pathways: mitochondrial reprogramming in tumor progression and therapy. *Clin Cancer Res*. 2016;22(3):540-545. [80] Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. *Nat Rev Cancer*. 2014;14(9):611-622. [81] Phan TG, Croucher PI. The dormant cancer cell life cycle. *Nat Rev Cancer*. 2020;20(7):398-411. [82] Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. *Cell Metab*. 2020;32(3):341-352. [83] Molina JR, Sun Y, Protopopova M, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. *Nat Med*. 2018;24(7):1036-1046. [84] Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. *Breast Cancer Res*. 2016;18(1):55. [85] Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. *Br J Cancer*. 2016;114(12):1305-1312. [86] Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. *PLoS ONE*. 2011;6(9):e24665. [87] Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional Chinese medicine. *J Ethnopharmacol*. 2012;140(3):634-642. [88] Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. *Cancer Lett*. 2007;252(1):43-54. [89] Chen HY, Lin YH, Chen YC. Identifying Chinese herbal medicine network for treating sarcopenia: implications from a nationwide database. *J Ethnopharmacol*. 2016;179:1-8. [90] Morikawa T, Ninomiya K, Imamura M, et al. Phenylethanoid oligoglycosides and acylated oligosugars with vasorelaxant activity from Cistanche tubulosa. *Bioorg Med Chem*. 2011;19(21):6413-6419. [91] Wang T, Chen C, Yang M, et al. Cistanche tubulosa ethanol extract mediates rat sex hormone levels by induction of testicular steroidogenic enzymes. *Pharm Biol*. 2016;54(3):481-487. [92] Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. *Thromb Haemost*. 2003;90(5):904-914. [93] Chang CZ, Wu SC, Kwan AL, Lin CL. Rhinacanthin-C, a fat-soluble extract from Rhinacanthus nasutus, modulates high-glucose-induced signaling transduction pathways and attenuates mitochondrial ROS production in endothelial cells. *Evid Based Complement Alternat Med*. 2012;2012:259165. [94] Wang X, Zhang H, Chen L, Shan L, Fan G, Gao X. Liquorice, a unique guide drug of traditional Chinese medicine: a review of its role in drug interactions. *J Ethnopharmacol*. 2013;150(3):781-790. [95] Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. *J Clin Pharmacol*. 2005;45(12):1345-1359. [96] Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. *Atherosclerosis*. 2012;220(1):3-10. [97] Valente P. The Bagua-Omics Framework: An Integrated Semiotic System for Multi-Omic Precision Medicine 2025-2035. Technical document; 2025. https://publish.obsidian.md/flosvitae/The+Bagua-Omics+Framework.+An+Integrated+Semiotic+System+for+Multi-Omic+Precision+Medicine+(2025–2035) [98] Auyeung KK, Han QB, Ko JK. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers. *Am J Chin Med*. 2016;44(1):1-22. [99] Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *J Natl Cancer Inst*. 2013;105(16):1230-1238. [100] Grossberg AJ, Scarlett JM, Marks DL. Hypothalamic mechanisms in cachexia. *Physiol Behav*. 2010;100(5):478-489. [101] Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem Pharmacol*. 1999;58(11):1685-1693. [102] Kim JH, Yi YS, Kim MY, Cho JY. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. *J Ginseng Res*. 2017;41(4):435-443. [103] Barton DL, Soori GS, Bauer BA, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation NCCTG trial N03CA. *Support Care Cancer*. 2010;18(2):179-187. [104] Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. *Cancer Epidemiol Biomarkers Prev*. 1995;4(4):401-408. [105] Cui Y, Shu XO, Gao YT, et al. Association of ginseng use with survival and quality of life among breast cancer patients. *Am J Epidemiol*. 2006;163(7):645-653. [106] Morikawa T, Xie H, Pan Y, et al. A review of biologically active natural products from a desert plant Cistanche tubulosa. *Chem Pharm Bull (Tokyo)*. 2019;67(7):675-689. [107] Huang LZ, Huang BK, Ye Q, Qin LP. Bioactivity-guided fractionation for anti-fatigue property of Acanthopanax senticosus. *J Ethnopharmacol*. 2011;133(1):213-219. [108] Ma ZC, Hong Q, Wang YG, et al. Feruloylated oligosaccharides and a lignan glycoside from the stems of Cistanche deserticola. *Molecules*. 2011;16(4):3112-3123. [109] Li Z, Lin H, Gu L, Gao J, Tzeng CM. Herba Cistanche (Rou Cong-Rong): one of the best pharmaceutical gifts of traditional Chinese medicine. *Front Pharmacol*. 2016;7:41. [110] Ren Y, Houghton PJ, Hider RC, Howes MJ. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. *Planta Med*. 2004;70(3):201-204. [111] Ji X, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. *Acta Pharmacol Sin*. 2000;21(12):1089-1094. [112] Chen X, Guo J, Bao J, Lu J, Wang Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. *Med Res Rev*. 2014;34(4):768-794. [113] Wasser S, Ho JM, Ang HK, Tan CE. Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats. *J Hepatol*. 1998;29(5):760-771. [114] Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol*. 2009;41(1):40-59. [115] Tao F, Qian C, Guo W, et al. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin. *Biochem Pharmacol*. 2013;85(6):798-807. [116] Reddy CA, Somepalli V, Golakoti T, et al. Mitochondrial-targeted curcuminoids: a strategy to enhance bioavailability and anticancer efficacy of curcumin. *PLoS ONE*. 2014;9(3):e89351. [117] Reddy CA, Somepalli V, Golakoti T, et al. Mitochondrial-targeted curcuminoids: a strategy to enhance bioavailability and anticancer efficacy of curcumin. *PLoS ONE*. 2014;9(3):e89351. [118] Ryan Wolf J, Heckler CE, Guido JJ, et al. Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. *Support Care Cancer*. 2018;26(5):1543-1552. [119] Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2006;4(8):1035-1038. [120] Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. *Clin Interv Aging*. 2014;9:451-458. [121] Och A, Podgórski R, Nowak R. Biological activity of berberine—a summary update. *Toxins (Basel)*. 2020;12(11):713. [122] Rauf A, Abu-Izneid T, Khalil AA, et al. Berberine as a potential anticancer agent: a comprehensive review. *Molecules*. 2021;26(23):7368. [123] Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism*. 2008;57(5):712-717. [124] Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. *Lancet Gastroenterol Hepatol*. 2020;5(3):267-275. [125] Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. *J Clin Endocrinol Metab*. 2008;93(7):2559-2565. [126] Wang Y, Huang Y, Lam KS, et al. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. *Cardiovasc Res*. 2009;82(3):484-492. [127] You L, Pan Y, Chen M, et al. The herbal medicine JPYS restores mitochondrial quality control in muscle atrophy of chronic kidney disease. *Biomed Pharmacother*. 2022;148:112728. [128] Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from rhubarb. *Med Res Rev*. 2007;27(5):609-630. [129] Argelaguet R, Velten B, Arnol D, et al. Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. *Mol Syst Biol*. 2018;14(6):e8124. [130] Peng L, Zhang K, Li Y, Chen L, Gao H, Chen H. Real-world evidence of Traditional Chinese Medicine (TCM) treatment on cancer: a literature-based review. *Evid Based Complement Alternat Med*. 2022;2022:7770380. [131] Deng GE, Frenkel M, Cohen L, et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. *J Soc Integr Oncol*. 2009;7(3):85-120. [132] Lyman GH, Greenlee H, Bohlke K, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. *J Clin Oncol*. 2018;36(25):2647-2655. # Supplementary Table S1 ## BaGuaNet-Omics Phytotherapeutic Intervention Matrix: 8 Trigram Domains × 7 Evidence-Based Medicinal **Evidence Level Key (Oxford CEBM):** 1a = Systematic review/Meta-analysis of RCTs | 1b = Individual RCT | 2a = Systematic review of cohort studies | 2b = Individual cohort study or low-quality RCT | 3 = Case-control study | 4 = Case series / poor-quality cohort | 5 = Expert opinion --- ## 乾 Qián (Heaven) — Glycolytic Hypermetabolism / Warburg Effect **Therapeutic Targets:** ↓mTOR, ↓HIF-1α, ↑AMPK, shift glycolysis→OXPHOS | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | | --- | --------------------------------- | ----------------------------- | ----------------------------------------------------------------------------------- | --------------------------------- | ------------------------------------ | ----- | --------------------------------------------------------------------------- | | 1 | **Berberis vulgaris** | Berberine | ↑AMPK (Thr172-P), ↓mTOR, ↓HK2, metabolic shift glycolysis→OXPHOS | 500 mg t.i.d. | RCT (T2DM, metabolic syndrome) | 2b | Avoid with metformin/antidiabetics; contraindicated in pregnancy | | 2 | **Camellia sinensis** | EGCG | ↓HIF-1α, ↓GLUT1, inhibition tumor glycolysis, apoptosis induction in Warburg+ cells | 400–800 mg/d | Meta-analysis (metabolic oncology) | 2a | May reduce bioavailability of iron supplements; caution with anticoagulants | | 3 | **Curcuma longa** | Curcumin (liposomal) | ↓NF-κB, ↓mTOR, ↑AMPK, ↓tumor lactate, chemotherapy sensitization | 1000 mg b.i.d. liposomal | RCT (colorectal cancer) | 1b | High doses may interfere with chemotherapy timing; ↑anticoagulant effect | | 4 | **Salvia miltiorrhiza (Danshen)** | Tanshinones, salvianolic acid | ↓HIF-1α, ↑microvascular perfusion, ↓tumor hypoxia | 1–2 g/d extract | TCM clinical (integrative oncology) | 3 | Potentiates anticoagulants (warfarin); caution with CYP2C9 substrates | | 5 | **Momordica charantia** | Charantin, polypeptide-p | ↑Insulin signaling, ↓GLUT1 hyperactivation, ↓insulin resistance | Extract 3–6 g/d | Pilot studies (pre-diabetes) | 4 | Additive hypoglycemic effect with insulin/antidiabetics | | 6 | **Panax ginseng** | Ginsenosides Rg3, Rh2 | ↓Tumor cell proliferation, metabolic pathway modulation, ↓angiogenesis | 200–400 mg/d standardized extract | Meta-analysis (lung, gastric cancer) | 1b | Avoid in uncontrolled hypertension; possible interaction with warfarin | | 7 | **Scutellaria baicalensis** | Baicalin, wogonin | ↓HIF-1α, PDK1 inhibition (pyruvate dehydrogenase kinase), forced OXPHOS metabolism | 1000–1500 mg/d extract | Advanced preclinical studies | 4 | Possible potentiation of chemotherapeutic agents; monitor liver enzymes | --- ## 坤 Kūn (Earth) — Metabolic Stagnation / Fibrosis / Lipotoxicity **Therapeutic Targets:** ↑Mitophagy, ↓Ceramides, ↓TGF-β/Smad, ↑PGC-1α | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | |---|-------|-------------------|------------------------|------|---------------|-------|-----------------------------| | 1 | **Silybum marianum** | Silymarin (80% silybin) | ↓TGF-β/Smad, hepatic antifibrotic, ↓collagen, ↑glutathione, hepatocyte membrane protection | 420 mg b.i.d. | Meta-analysis (NASH/MASH, cirrhosis) | 1a | Generally well-tolerated; mild laxative effect at high doses | | 2 | **Punica granatum (Pomegranate)** | Urolithin A (ellagitannin metabolite) | Potent mitophagy inducer, dysfunctional mitochondria clearance, ↓visceral ceramides | 500–1000 mg/d | Phase II RCT (muscle function, aging) | 2b | Minimal; may enhance effect of immunosuppressants in transplant patients | | 3 | **Glycyrrhiza glabra (Licorice)** | Glycyrrhizin, isoliquiritigenin | ↓Hepatic/pulmonary fibrosis, M2 macrophage modulation, ↓pro-fibrotic cytokines | 200–400 mg/d DGL form | Clinical studies (NASH, pulmonary fibrosis) | 2b | Avoid high-dose non-DGL form: pseudohyperaldosteronism, hypokalemia, hypertension | | 4 | **Salvia rosmarinus (Rosemary)** | Rosmarinic acid, carnosol | ↑Mitophagy, ↑autophagy, potent antioxidant, ↓ER stress, cardiolipin protection | 500 mg b.i.d. extract | Preclinical + traditional use | 4 | Avoid in pregnancy (emmenagogue); caution with anticoagulants | | 5 | **Schisandra chinensis (Wu Wei Zi)** | Schisandrin B, gomisin N | Mitochondrial function restoration, ↓hepatic lipotoxicity, ↑β-oxidation | 500 mg b.i.d. extract | TCM + pharmacological studies (NAFLD) | 3 | Induces CYP3A4: may reduce plasma levels of tacrolimus, statins, some chemotherapeutics | | 6 | **Paeonia lactiflora (White Peony)** | Paeoniflorin | Multi-organ antifibrotic, ↓TGF-β1, immune modulation, ↓activated fibroblasts | 600–1200 mg/d extract | TCM + RCT (systemic sclerosis, fibrosis) | 2b | Mild; possible hypotension at high doses; caution with antihypertensives | | 7 | **Arctium lappa (Burdock)** | Arctigenin | ↓Hepatic lipid accumulation, ↑insulin sensitivity, ↓oxidative stress in visceral adipose | Root 2–4 g/d decoction | Traditional phytotherapy + preliminary evidence | 5 | Generally safe; mild diuretic; caution in allergy to Asteraceae family | --- ## 震 Zhèn (Thunder) — Mitochondrial Biogenesis / Healthy Anabolism **Therapeutic Targets:** ↑PGC-1α, ↑NRF1/TFAM, ↑Complexes I–V, ↑NAD⁺ | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | |---|-------|-------------------|------------------------|------|---------------|-------|-----------------------------| | 1 | **Panax ginseng (Korean ginseng)** | Ginsenosides Rg1, Rb1 | ↑PGC-1α, ↑mitochondrial biogenesis, ↑fatigue resistance, ↑physical performance | 200–400 mg/d standardized extract | RCT (athletic performance, aging) | 1b | Avoid uncontrolled hypertension; possible interaction with warfarin/anticoagulants | | 2 | **Rhodiola rosea** | Salidroside, rosavins (3:1) | ↑Mitochondrial biogenesis, ↑PGC-1α, adaptogen, ↑stress resistance, ↑ATP | 400 mg b.i.d. (3% rosavins) | Meta-analysis (fatigue, stress, cognition) | 1a | Caution in bipolar disorder; possible stimulant effect; avoid evening dosing | | 3 | **Withania somnifera (Ashwagandha)** | Withanolides (withaferin A) | ↑PGC-1α, ↑NRF2, ↑mitochondrial SOD2, neuroprotective, ↑muscle strength | 300–600 mg b.i.d. KSM-66 | RCT (muscle strength, anxiety, sleep) | 1b | Caution in hyperthyroidism (↑T3/T4); caution in autoimmune disease; avoid in pregnancy | | 4 | **Cordyceps sinensis/militaris** | Cordycepin, polysaccharides | ↑ATP, ↑oxygen utilization (VO₂max), ↑mitochondrial respiratory function, ↑endurance | 1–3 g/d mushroom | Clinical studies (athletes, renal insufficiency) | 2b | Caution with immunosuppressants; possible anticoagulant potentiation | | 5 | **Eleutherococcus senticosus (Siberian ginseng)** | Eleutherosides | Adaptogen, ↑physical work capacity, ↑mitochondrial biogenesis, ↓post-exercise lactate | 300–1200 mg/d extract | Soviet studies + recent validations | 3 | Mild; possible interaction with digoxin (interferes with assay); avoid in hypertension | | 6 | **Ginkgo biloba** | Flavonoids, terpenes (ginkgolides) | ↑Cerebral perfusion, ↑neuronal mitochondrial respiration, antioxidant, ↑memory | 120–240 mg/d EGb 761 | Meta-analysis (cognitive decline, dementia) | 1a | Potentiates anticoagulants/antiplatelets; discontinue before surgery | | 7 | **Centella asiatica (Gotu kola)** | Asiaticoside, madecassoside | ↑BDNF, ↑neuronal mitochondrial biogenesis, ↑wound healing, ↑collagen type I | 500–1000 mg/d extract | RCT (cognitive, wound healing) | 2b | Generally safe; rare hepatotoxicity at very high doses; caution with sedatives | --- ## 坎 Kǎn (Water) — Mitochondrial Stress / Bioenergetic Depletion **Therapeutic Targets:** ↓GDF15/FGF21, ↑NAD⁺, ↓ATF4/CHOP, ↓Lactate/Pyruvate, ↑Complex I support | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | | --- | -------------------------------------- | --------------------------------------- | ------------------------------------------------------------------------------------- | ------------------------------- | ----------------------------------------- | ----- | ------------------------------------------------------------------------------------ | | 1 | **Rhodiola rosea** | Salidroside, rosavins | ↓ATF4/CHOP (ISR), ↑NAD⁺, ↓cortisol, HPA axis modulation, anti-stress adaptogen | 300–600 mg/d | Meta-analysis (chronic fatigue, stress) | 1a | Caution in bipolar disorder; possible stimulant effect; avoid evening dosing | | 2 | **Withania somnifera (Ashwagandha)** | Withanolides | ↓Cortisol (up to 30%), ↓oxidative stress, ↑NAD⁺, ↓GDF15, neuroprotective | 300–600 mg b.i.d. KSM-66 | RCT (chronic stress, anxiety, Long COVID) | 1b | Caution in hyperthyroidism; autoimmune disease; avoid in pregnancy | | 3 | **Astragalus membranaceus (Huang Qi)** | Astragalosides IV, polysaccharides | ↑ATP, ↑Complex I activity, ↓fatigue, immunomodulation, ↑telomerase activity | 2–4 g/d root decoction | TCM + RCT (heart failure, CFS, oncology) | 2b | Generally safe; caution with immunosuppressants (transplant patients) | | 4 | **Schisandra chinensis (Wu Wei Zi)** | Schisandrin, gomisin | Mitochondrial function restoration, ↓oxidative stress, ↑glutathione, hepatoprotective | 500 mg b.i.d. | TCM + pharmacological studies | 3 | CYP3A4 inducer: reduces plasma levels of tacrolimus, statins, some chemotherapeutics | | 5 | **Camellia sinensis (Matcha)** | L-theanine + EGCG | ↑NAD⁺ (via NAMPT), ↓ROS, ↑α-ketoglutarate, ↑focus without stimulant jitter | 200 mg L-theanine + 400 mg EGCG | Clinical studies (cognition, stress) | 2b | See EGCG interactions above; L-theanine generally safe | | 6 | **Glycine max / Natto (fermented)** | NAD⁺ precursors from fermentation (NMN) | Direct NAD⁺ precursor, ↑SIRT1/3, ↑biogenesis, ↓senescence | Functional food 50–100 g/d | Japanese nutritional evidence | 4 | Avoid with anticoagulants (high vitamin K content in natto) | | 7 | **Vaccinium myrtillus (Bilberry)** | Anthocyanins, pterostilbene | ↑NAD⁺/NADH ratio, mitochondrial antioxidant, ↑memory, ↓neural inflammation | Extract 160 mg b.i.d. | RCT (cognition, memory in elderly) | 2b | May potentiate antiplatelet/anticoagulant drugs | --- ## 艮 Gèn (Mountain) — Dynamic Blockade / Mitochondrial Fragmentation **Therapeutic Targets:** ↑Fusion (MFN2/OPA1), ↓Fission (DRP1-pS616), ↑Mitophagy PINK1/Parkin, ↑Cardiolipin | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | |---|-------|-------------------|------------------------|------|---------------|-------|-----------------------------| | 1 | **Punica granatum (Pomegranate)** | Urolithin A | PINK1/Parkin-independent mitophagy inducer, clearance of fragmented mitochondria | 500–1000 mg/d | Phase II RCT (muscle function) | 2b | Minimal; caution in immunosuppressed patients | | 2 | **Polygonum cuspidatum (Hu Zhang)** | Resveratrol, polydatin | ↑SIRT1, ↑mitophagy, ↓mitochondrial ROS, ↑OPA1, cardioprotective | 150–500 mg/d resveratrol | RCT (CVD, aging, neuroprotection) | 2b | May potentiate anticoagulants; possible interaction with CYP1A2/3A4 substrates | | 3 | **Crataegus monogyna/oxyacantha (Hawthorn)** | Oligomeric proanthocyanidins | ↑Cardiac contractility, ↑coronary perfusion, membrane stabilization, ↑cardiolipin | 160–900 mg/d extract WS 1442 | Meta-analysis (heart failure NYHA II–III) | 1a | Possible interaction with digoxin and antihypertensives; gradual dose escalation recommended | | 4 | **Salvia miltiorrhiza (Danshen)** | Tanshinone IIA, cryptotanshinone | ↑Mitochondrial fusion, ↓fragmentation, ↓cardiomyocyte apoptosis, ↑microcirculation | 1–2 g/d extract | TCM + RCT (angina, CVD) | 2b | Potentiates anticoagulants (warfarin); caution with CYP2C9 substrates | | 5 | **Ginkgo biloba** | Ginkgolides, bilobalide | Mitochondrial membrane stabilization, ↑cardiolipin, ↓oxidative stress, neuroprotective | 120–240 mg/d EGb 761 | Meta-analysis (dementia, neuropathy) | 1a | Potentiates anticoagulants/antiplatelets; discontinue 2 weeks before surgery | | 6 | **Vitis vinifera (Grape seed)** | Oligomeric proanthocyanidins (OPC) | Membrane antioxidant, ↓lipid peroxidation, cardiolipin protection, ↓ROS | 150–300 mg/d | Clinical studies (CVD, venous insufficiency) | 2b | May potentiate antiplatelet drugs | | 7 | **Terminalia arjuna** | Arjunolic acid, arjunetin | Cardioprotective, ↑ventricular function, ↓cardiac oxidative stress, ↑ATP | 500 mg t.i.d. bark extract | Ayurveda + RCT (heart failure) | 2b | Possible hypotension; caution with antihypertensives and cardiac glycosides | --- ## 巽 Xùn (Wind) — Neurovegetative Instability / Dysautonomia **Therapeutic Targets:** ↑HRV (RMSSD), ↓glycemic oscillations, ↓catecholamines, ↑CLOCK/BMAL1 synchronization | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | |---|-------|-------------------|------------------------|------|---------------|-------|-----------------------------| | 1 | **Rhodiola rosea** | Salidroside (1%), rosavins (3%) | ↑HRV, ↓cortisol, CNS-autonomic modulation, anti-fatigue, adaptogen | 300–600 mg/d | RCT (HRV, stress, fatigue) | 1b | Caution in bipolar disorder; mild stimulant; avoid evening dosing | | 2 | **Melissa officinalis (Lemon balm)** | Rosmarinic acid, citronellal | GABAergic anxiolytic, ↓sympathetic arousal, ↑parasympathetic tone, ↑sleep quality | 300–600 mg/d extract | RCT (anxiety, sleep, POTS) | 2b | May potentiate sedatives and thyroid hormone inhibition; caution in hypothyroidism | | 3 | **Lavandula angustifolia (Lavender)** | Linalool, linalyl acetate | Autonomic modulation via olfactory pathway, ↓HR, ↓BP, anxiolytic | 80–160 mg/d capsules (Silexan) | RCT (generalized anxiety, sleep quality) | 1b | Possible CYP inhibition at high doses; avoid with CNS depressants | | 4 | **Valeriana officinalis (Valerian)** | Valerenic acid, valepotriates | GABAergic, ↑deep sleep, ↓sleep onset latency, autonomic rhythm stabilization | 300–900 mg/d extract | Meta-analysis (insomnia, anxiety) | 1a | Additive CNS depression with benzodiazepines/sedatives; avoid with alcohol | | 5 | **Passiflora incarnata (Passionflower)** | Flavonoids (apigenin, chrysin) | GABAergic anxiolytic, ↓sympathovagal oscillations, ↑cerebral GABA | 500 mg b.i.d.–t.i.d. extract | RCT (pre-operative anxiety, GAD) | 2b | Additive effect with benzodiazepines/sedatives; avoid in pregnancy | | 6 | **Crocus sativus (Saffron)** | Safranal, crocin | Antidepressant (↑serotonin), HPA modulation, ↑emotional stability, ↓mood variability | 30 mg/d stigmas | RCT (mild-moderate depression) | 1b | Possible potentiation of SSRIs (serotonin syndrome risk at high doses) | | 7 | **Magnolia officinalis** | Honokiol, magnolol | Non-sedative anxiolytic, GABA_A modulation, ↓cortisol, neuroprotective | 200–400 mg/d bark extract | Pilot studies (anxiety, sleep disorders) | 4 | Caution with CNS depressants; possible CYP3A4 inhibition | --- ## 離 Lí (Fire) — Inflammation / Oxidative Stress / SASP **Therapeutic Targets:** ↓NF-κB, ↓IL-6/TNF-α, ↓ROS, ↑GSH, ↓8-OHdG, senolytic | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | |---|-------|-------------------|------------------------|------|---------------|-------|-----------------------------| | 1 | **Curcuma longa** | Curcumin (liposomal/piperine) | ↓NF-κB, ↓COX-2, ↓iNOS, senolytic, ↓IL-6/TNF-α, mitochondrial function preservation | 500–2000 mg/d bioavailable form | Meta-analysis (arthritis, NASH, aging) | 1a | High doses may interfere with chemotherapy (critical timing); ↑anticoagulant effect | | 2 | **Camellia sinensis (Green tea)** | EGCG, polyphenols | ↓ROS, ↑NRF2 (endogenous antioxidants), ↓NF-κB, ↓SASP, senomorphic | 400–800 mg/d EGCG | Meta-analysis (inflammaging, CVD, cancer) | 1a | Reduce iron supplement absorption; caution with anticoagulants | | 3 | **Boswellia serrata (Indian frankincense)** | Boswellic acids (AKBA) | 5-lipoxygenase inhibitor, ↓leukotrienes, potent anti-inflammatory, ↓cytokines | 300–500 mg t.i.d. 65% boswellic acid extract | RCT (arthritis, IBD, asthma) | 1b | Generally safe; possible GI irritation; no major drug interactions known | | 4 | **Zingiber officinale (Ginger)** | Gingerols, shogaols | ↓NF-κB, ↓COX-2, ↓ROS, GI anti-inflammatory, immunomodulator | 1–3 g/d fresh root or 250 mg extract | RCT (arthritis, nausea, inflammaging) | 1b | Potentiates anticoagulants at high doses; caution with antidiabetics | | 5 | **Polygonum cuspidatum (Hu Zhang)** | Resveratrol, polydatin | Senolytic, ↑SIRT1, ↓mitochondrial ROS, ↓SASP, anti-aging | 150–500 mg/d trans-resveratrol | RCT + preclinical longevity evidence | 2b | Potentiates anticoagulants; CYP1A2/3A4 interaction | | 6 | **Allium sativum (Garlic)** | Allicin, S-allyl cysteine | ↓NF-κB, ↓ROS, ↑glutathione, cardioprotective, immunomodulator | Aged extract 600–1200 mg/d | Meta-analysis (CVD, hypertension) | 1a | Potentiates anticoagulants/antiplatelets; avoid before surgery | | 7 | **Matricaria chamomilla (Chamomile)** | Apigenin, α-bisabolol | Intestinal anti-inflammatory, ↓NF-κB, ↓IL-6, gentle antioxidant, GABA modulator | 300–400 mg/d extract or 3×/d infusion | Clinical studies (IBD, anxiety, sleep) | 2b | Allergy risk (Asteraceae family); may potentiate anticoagulants and sedatives | --- ## 兌 Duì (Lake) — Metabolic Resilience / Adaptive Flexibility **Therapeutic Targets:** ↑AMPK/SIRT1, ↑fuel flexibility, ↑optimal NAD⁺/NADH, ↑adaptive mitophagy | # | Plant | Active Principles | Mitochondrial Mechanism | Dose | Evidence Base | Level | Key Interactions / Cautions | |---|-------|-------------------|------------------------|------|---------------|-------|-----------------------------| | 1 | **Camellia sinensis (Matcha)** | EGCG + L-theanine | ↑AMPK, ↑fat oxidation, ↑fuel flexibility, ↑NAD⁺, ↑SIRT1, ↑focus | 200 mg L-theanine + 400 mg EGCG | RCT (metabolism, cognition, performance) | 1b | See EGCG above; L-theanine generally safe; avoid high doses during chemotherapy | | 2 | **Panax ginseng** | Ginsenosides Rg1, Rb1, Rg3 | Complete adaptogen, ↑AMPK, ↑metabolic flexibility, ↑multi-level stress resistance | 200–400 mg/d extract | Meta-analysis (performance, resilience, longevity) | 1b | Avoid in uncontrolled hypertension; possible warfarin interaction | | 3 | **Olea europaea (Olive)** | Oleuropein, hydroxytyrosol | ↑AMPK, ↑SIRT1, ↑insulin sensitivity, anti-inflammaging, cardioprotective | Leaf extract 500 mg/d or EVO 30–50 mL/d | Mediterranean Diet epidemiological studies | 2a | Generally safe; may mildly potentiate antihypertensives | | 4 | **Vitis vinifera (Red grape)** | Resveratrol, quercetin, proanthocyanidins | ↑SIRT1, ↑PGC-1α, ↑mitophagy, ↑longevity in preclinical models, cardioprotective | 150–300 mg/d resveratrol | Longevity studies (C. elegans, Drosophila, mouse) | 3 | Potentiates anticoagulants; CYP interaction | | 5 | **Vaccinium spp. (Blueberry)** | Anthocyanins, pterostilbene | ↑NAD⁺/NADH, antioxidant, ↑memory, ↑cerebrovascular flexibility, anti-aging | Fresh fruit 150 g/d or extract 500 mg | RCT (cognition in elderly, CVD) | 2b | Mild antiplatelet effect | | 6 | **Moringa oleifera** | Isothiocyanates, quercetin | ↑NRF2, ↑glutathione, nutritionally dense (proteins, vitamins), tropical adaptogen | Leaf powder 5–10 g/d | Nutritional studies (malnutrition, metabolism) | 3 | Generally safe; caution in pregnancy (uterotonic at high doses) | | 7 | **Gynostemma pentaphyllum (Jiaogulan)** | Gypenosides (saponins) | ↑AMPK, ↑SIRT1, adaptogen, ↑telomerase, longevity properties | 3–9 g/d leaf infusion | TCM + preliminary longevity studies | 4 | Generally safe; possible additive effect with antidiabetics/antihypertensives | --- ## Clinical Combination Protocols: Representative Hexagram States | Hexagram State | Clinical Context | Priority Interventions | |----------------|-----------------|------------------------| | **坎巽 Kǎn–Xùn** | Long COVID / CFS / Dysautonomia | Rhodiola 400 mg b.i.d. · Ashwagandha 300 mg b.i.d. · CoQ10 ubiquinol 200 mg/d · NMN 500 mg/d · Astragalus 2–3 g/d | | **坤離 Kūn–Lí** | MASH / Hepatic Fibrosis + Inflammation | Silymarin 420 mg b.i.d. · Urolithin A 500 mg/d · Berberine 500 mg t.i.d. · Curcumin 1000 mg b.i.d. liposomal · Resveratrol 250 mg/d | | **艮坎 Gèn–Kǎn** | CVD + Mitochondrial Fragmentation | Hawthorn 900 mg/d · Resveratrol 250 mg/d · Urolithin A 500 mg/d · CoQ10 200–400 mg/d · Danshen 1–2 g/d | | **乾離 Qián–Lí** | Warburg+ Tumor + Systemic Inflammation | Berberine 500 mg t.i.d. · Curcumin 1000 mg b.i.d. · EGCG 600 mg/d · Scutellaria 1000 mg/d · Boswellia 1500 mg/d | --- ## General Safety Notes - All protocols require **clinical supervision** and individualized risk-benefit assessment. - **Anticoagulant interaction**: Resveratrol, Ginkgo, Danshen, Garlic, Ginger, Bilberry — verify INR/PT in patients on warfarin or antiplatelet therapy. - **Chemotherapy timing**: Curcumin and EGCG may interfere with specific cytotoxic agents; administer at least 2 hours apart or according to oncologist guidance. - **CYP3A4 inducers**: Schisandra may reduce plasma levels of tacrolimus, cyclosporine, and several targeted therapies. - **Thyroid-active plants**: Ashwagandha and Rhodiola may modulate thyroid function; monitor TSH/T3/T4 in patients with thyroid pathology. - Patients with **autoimmune disease or organ transplant** require specialist review before use of immunomodulatory herbs.